Bifunctional compounds useful as ras protein degraders
Bifunctional compounds targeting Ras proteins for degradation offer a solution to overcome limitations in existing therapeutics by effectively inhibiting Ras signaling and treating associated diseases through enhanced protein degradation.
Patent Information
- Application Number
- PCT/US2026/026921
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing therapeutics targeting Ras proteins, particularly those with G12C mutations, face limitations due to low prevalence and drug resistance, making it difficult to effectively inhibit Ras signaling and treat Ras-associated diseases like cancer.
Development of bifunctional compounds capable of binding to Ras proteins and enhancing their degradation, including specific inhibitors targeting mutant Ras proteins such as G12D, G12C, G12S, G13D, and/or G12V, along with methods for synthesizing such compounds.
These compounds effectively reduce Ras signaling output and enhance protein degradation, providing a potential therapeutic approach for treating various diseases, including cancers and neoplasia conditions.
Smart Images

Figure US2026026921_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No. 56690-815601
[0002] BIFUNCTIONAL COMPOUNDS USEFUL AS RAS PROTEIN DEGRADERSCROSS-REFERENCE
[0003]
[0001] This application claims the benefit of U. S. Provisional Application No. 63 / 801,721, filed May 7, 2025, incorporated herein by reference in its entirety.
[0004] SEQUENCE LISTING
[0005]
[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 24, 2026, is named 56690_815_601_SL.xml and is 15,018 bytes in size.
[0006] BACKGROUND
[0007]
[0003] Cancer (e.g., tumor, neoplasm, metastases) is the second leading cause of death worldwide estimated to be responsible for about 10 million deaths each year. Many types of cancers are marked with mutations in one or more proteins involved in various signaling pathways leading to unregulated growth of cancerous cells. In some cases, about 25 to 30 percent (%) of tumors are known to harbor Rat sarcoma (Ras) mutations. In particular, mutations in the Kirsten Ras oncogene (K-Ras) are one of the most frequent Ras mutations detected in human cancers, including lung adenocarcinomas (LUADs) and pancreatic ductal adenocarcinoma (PDAC).
[0008]
[0004] Ras proteins have long been considered “undruggable,” due to, in part, high affinity to their substrate guanosine-5'-triphosphate (GTP) and / or their smooth surfaces without any obvious targeting region. The specific G 12C Ras gene mutation has been identified as a druggable target to which a number of G 12C specific inhibitors have been developed. However, such therapeutics are still of limited application, as the G 12C mutation in Ras exhibits a much lower prevalence rate as compared to other known Ras mutations, such as G12D and G12V. Drug resistance and lack of durability impose further limitations to such therapeutics.
[0009] SUMMARY
[0010]
[0005] In view of the foregoing, there remains a considerable need for a new design of therapeutics and diagnostics that can specifically target Ras, including wildtype Ras, mutants and / or associated proteins of Ras to reduce Ras signaling output. Of particular interest are Ras inhibitors, including pan Ras inhibitors capable of inhibiting two or more Ras mutants and / or wildtype Ras, as well as mutant-selective inhibitors targeting mutant Ras proteins such as Ras G12D, G12C, G12S, G13D, and / or G12V, for the treatment of Ras-associated diseases (e.g., cancer). Of further interest are Ras-specific protein degrader compounds that are capable of binding to a Ras protein and enhancing the degradation of the Ras protein. Of additional interest are methods of synthesizing such Ras protein specific degraders along with new compounds that are useful in those synthetic methods. Such compositions and methods can be particularly useful for treating a variety of diseases including, but not limited to, cancers and neoplasia conditions. The present disclosure addresses these needs, and provides additional advantages applicable for diagnosis, prognosis, and / or treatment for a wide diversity of diseases.
[0011]
[0006] In an aspect is provided a compound of Formula (A):Attorney Docket No. 56690-815601
[0012]
[0013] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0014] Z1is selected from N and N(RBlb);
[0015] Z2is selected from C(RB2) and C(O);
[0016] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0017] Z7is selected from C(RB7) and N(RB7b);
[0018] Z8is selected from C(RB8), C(RB8)2, and N;
[0019] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0020] J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0021] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB2°;
[0022] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°;
[0023] DG is a degradation enhancer;
[0024] nl is selected from 1, 2, and 3;
[0025] RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0026] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-memberedAttomey Docket No. 56690-815601
[0027] heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;
[0028] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0029] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;
[0030] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0031] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-12 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-12 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0032] RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0033] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-Attorney Docket No. 56690-815601
[0034] 12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0035] RB23is independently selected at each occurrence from hydrogen and Ci-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0036] indicates a single or double bond such that all valences are satisfied.
[0037]
[0007] In some embodiments, the degradation enhancer is capable of binding a protein selected from E3A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperon-mediated autophage), SCFb-TRCP (Skip-Cullin-F box (Beta-TRCP) ubiquitin complex), b-TRCP (b-transducing repeat-containing protein), cIAPl (cellular inhibitor of apoptosis protein 1), APC / C (anaphase-promoting complex / cyclosome), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, iberdomide, and CC-885. In some embodiments, degradation enhancer is capable of binding a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1. In some embodiments, DG is selected from:
[0038]
[0039] wherein: J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3-to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, Ci-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O); RB20is independently selected at each occurrence from halogen, oxo, -CN, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atomsAttorney Docket No. 56690-815601
[0040] optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, - S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23); RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH; RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle); and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle. In some embodiments, DG is
[0041]
[0042]
[0008] In an aspect is provided a method of preparing a compound of Formula (A):
[0043]
[0044] the method comprising:
[0045] (a) reacting a compound of Formula (a):
[0046]
[0047] with a degradation enhancer under conditions to effect release of LG and production of the compound of Formula (A), wherein:
[0048] Z1is selected from N and N(RBlb);
[0049] Z2is selected from C(RB2) and C(O);
[0050] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0051] Z7is selected from C(RB7) and N(RB7b);Attorney Docket No. 56690-815601
[0052] Z8is selected from C(RB8), C(RB8)2, and N;
[0053] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB20;
[0054] J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB20;
[0055] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB20;
[0056] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;
[0057] DG is a degradation enhancer;
[0058] LG is a leaving group;
[0059] nl is selected from 1, 2, and 3;
[0060] RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0061] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;Attorney Docket No. 56690-815601
[0062] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0063] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0064] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0065] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0066] RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0067] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0068] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0069] indicates a single or double bond such that all valences are satisfied.
[0070]
[0009] In an aspect is provided a compound of Formula (a):Attorney Docket No. 56690-815601
[0071]
[0072] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0073] Z1is selected from N and N(RBlb);
[0074] Z2is selected from C(RB2) and C(O);
[0075] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0076] Z7is selected from C(RB7) and N(RB7b);
[0077] Z8is selected from C(RB8), C(RB8)2, and N;
[0078] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0079] J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0080] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB2°;
[0081] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°;
[0082] LG is selected from -OS(O)2RB4and -OS(O)(NRB4b)RB4;
[0083] nl is selected from 1, 2, and 3;
[0084] RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), and -N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0085] RBlb, RB4b, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -Attorney Docket No. 56690-815601
[0086] S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0087] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;
[0088] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0089] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0090] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0091] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);Attomey Docket No. 56690-815601
[0092] RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0093] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0094] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0095] indicates a single or double bond such that all valences are satisfied.
[0096]
[0010] In some embodiments, ZB5is C(RB9)2. In some embodiments, nl is 1. In some embodiments, Q2is 7- to 9-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB2°. In some embodiments,
[0097]
[0098] , which is optionally substituted with one or more RB2°.
[0099]
[0011] In some embodiments, Z1is N, Z2is C(RB2), Z6is C(RB6), Z7is C(RB7), and Z8is C(RB8); Z1is N, Z2is C(RB2), Z6is N, Z7is C(RB7), and Z8is C(RB8); Z1is N, Z2is C(RB2), Z6is C(RB6)2, Z7is N(RB7b), and Z8is C(RB8)2; or Z1is N(RBlb), Z2is C(O), Z6is C(RB6), Z7is C(RB7), and Z8is N. In some embodiments, Z1is N, Z2is C(RB2), Z6is C(RB6), Z7is C(RB7), and Z8is C(RB8). In some embodiments, Z1is N, Z2is C(RB2), Z6is N, Z7is C(RB7), and Z8is C(RB8).
[0100]
[0012] In some embodiments, J1is selected from a bond, Ci-e alkylene, 2- to 6-membered heteroalkylene, and -C(O)-, wherein C1-6 alkylene and 2- to 6-membered heteroalkylene are optionally substituted with one or more RB2°. In some embodiments, J1is -C(O)-. In some embodiments, J2is a bond. In some embodiments, J3is selected from C1-6 alkylene and 2- to 6-membered heteroalkylene, each of which is optionally substituted with one or more RB2°. In some embodiments, J1is -C(O)-; J2is a bond; and J3is Ci-e alkylene.
[0101]
[0013] In some embodiments, the compound has the formula:
[0102]
[0103] , wherein:-J1-J2-J3-
[0104]
[0105] some embodiments, the compound has the formulaAttorney Docket No. 56690-815601
[0106] j3-LG
[0107] J1'J"
[0108] y.„r
[0109] O N— /
[0110] Y k H II ' o p' °S^ /
[0111] RBT y N' R62 / 6
[0112] F (a-7), wherein -J1-J2-J3-LG is /
[0113]
[0014] In some embodiments, RB2is selected from: (i) -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene) -(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein Ci-e alkyl, C3-4 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, and C1-6 haloalky 1; RB22is independently selected at each occurrence from hydrogen, Ci-e alkyl, C1-6 haloalkyl, C3-4 carbocycle, and 3- to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and Ci-e alkyl; (ii) -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein the (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle; (iii) -O(C2.3 alkylene)(pyrrolidine), wherein the pyrrolidine is substituted with two or three substituents independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2; (iv) -O(Ci-3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms) optionally substituted with one unsubstituted C1-3 alkyl; and (v) -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene) -(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence from hydrogen and halogen.
[0114]
[0015] In some embodiments, RB2is -O(Ci-3 alkylene)(4- to 10-membered heterocycle), wherein 4- to 10-membered heterocycle is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, -C0-1 alkyl-(C3-4 carbocycle) optionally substituted with one or more halogen, 4- to 8-membered heterocycle, -(2- to 3 -membered heteroalky l)-( C3-4 carbocycle) optionally substituted with one or more substituents selected from oxo and C1-3 alkyl, and =C(RB21)2, wherein RB21is independently selected at each occurrence from
[0115]
[0116] Attorney Docket No. 56690-815601
[0117]
[0118] 3- 4 carbocycle) optionally substituted with one or more halogen, 4- to 8-membered heterocycle, and -(2- to 3-membered heteroalkyl)-(C3-4 carbocycle) optionally substituted with one or more substituents selected from oxo and
[0119] Ci -3 alkyl. In some embodiments, RB2is selected from
[0120]
[0121]
[0122] some embodiments, RB2is -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(4- to 10-membered heterocycle) optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22. In some
[0123]
[0124] Attorney Docket No. 56690-815601
[0125]
[0126] embodiments, RB2is -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, and C1-6 haloalkyl, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH; RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-4 carbocycle, and 3-to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In
[0127] some embodiments, RB2is selected from
[0128]
[0129] Attorney Docket No. 56690-815601
[0130]
[0131]
[0132] some embodiments, RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with one, two, or three substituents independently selected from halogen, -CN, C1-3 alkyl, -C0-1 alkyl-(C3-6 carbocycle), and 4- to 6-membered heterocycle; wherein C1-3 alkyl, C0-1 alkyl-(C3-6 carbocycle), and 4- to 6-membered heterocycle, are optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C2-6 alkenyl, and C3-6 carbocycle. In some embodiments, RB2is
[0133]
[0134] Attorney Docket No. 56690-815601
[0135]
[0136] -O(Ci.
[0137] 3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle.
[0138] In some embodiments, RB2is selected from
[0139]
[0140]
[0141] embodiments, RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl. In some embodiments, RB2is selected from
[0142]
[0143] is substituted with two or three substituents independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2. In some embodiments,
[0144]
[0145] wherein R20is independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2. In some
[0146] embodiments, RB2is selected from
[0147]
[0148]
[0149] Attorney Docket No. 56690-815601
[0150] some embodiments, RB2is -O(Ci-3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms), optionally substituted with one unsubstituted C1-3 alkyl. In some embodiments, RB2is selected from
[0151]
[0152] is -O(Ci.3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence
[0153]
[0154] membered heterocycle), wherein the 6-membered heterocycle comprises one or two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(6-membered heterocycle) is optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, -C0-1 alkyl-(C3-4 carbocycle), 3- to 5-membered heterocycle, -ORB22, -N(RB22)(RB23), and -C(O)RB22; wherein C1-6 alkyl and 3- to 5-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, -ORB22, and -N(RB22)(RB23); RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, and C3-4 carbocycle; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In some
[0155]
[0156] Attorney Docket No. 56690-815601
[0157]
[0158]
[0016] In some embodiments, RB6is halogen or C1-3 haloalkyl. In some embodiments, RB7is selected from Ce i2 aryl and 5- to 12-membered heteroaryl, each of which is optionally substituted with one or more RB20. In some embodiments, RB7is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more RB20. In some embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, C2-3 alkynyl, -ORB22, -N(RB22)(RB23), and C3-6 cycloalkyl. In some embodiments, RB7is substituted with
[0159]
[0160]
[0161] Attorney Docket No. 56690-815601
[0162]
[0163] embodiments,
[0164]
[0165] some embodiments,
[0166]
[0167] some embodiments, RB7is
[0168]
[0169]
[0017] In some embodiments, RB8is halogen. In some embodiments, RB6is halogen; RB7is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more RB20; and RB8is halogen.
[0170]
[0018] In certain aspects, the present disclosure provides a compound selected from Table 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the present disclosure provides a compound selected from compound 101-171 of Table 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the present disclosure provides a compound selected from compound 172-258 of Table 1, or a pharmaceutically acceptable salt or solvate thereof.
[0171]
[0019] In an aspect is provided a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0172]
[0020] In an aspect is provided a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof. In an aspect is provided a method of treating cancer in a subject comprising a Ras mutant protein, the method comprising: inhibiting the Ras mutant protein of said subject by administering to said subject a compound described herein, wherein the compound is characterized in that upon contacting the Ras mutant protein, said Ras mutant protein exhibits reduced Ras signaling output. In some embodiments, the cancer is a solid tumor or a hematological cancer. In an aspect is provided a method of reducing signaling output of a Ras protein, comprising contacting a Ras protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing the signaling output of the Ras protein. In some embodiments, the compound binds covalently or non-covalently to the Ras protein, thereby reducing the signaling output of the Ras protein. In an aspect is provided a method of inhibiting cell growth, comprising administering an effective amountAttorney Docket No. 56690-815601
[0173] of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, to a cell expressing a Ras protein, thereby inhibiting growth of said cells. In some embodiments, the method comprises administering an additional agent.
[0174] INCORPORATION BY REFERENCE
[0175]
[0021] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0176] BRIEF DESCRIPTION OF THE DRAWINGS
[0177]
[0022] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0178]
[0023] FIG. 1 depicts a sequence alignment of various wild type Ras proteins including K-Ras, H-Ras, N-Ras, RalA, and RalB, from top to bottom.
[0179] DETAILED DESCRIPTION
[0180]
[0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs. In the event that there are a plurality of definitions for terms herein, those in this section prevail. All patents, patent applications, publications and published nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) referred to herein are incorporated by reference. Chemical structures are named herein according to IUPAC conventions as implemented in ChemDraw® software (Perkin Elmer, Inc., Cambridge, MA). The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes”, and “included”, is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0181]
[0025] The term “Cx-y” or “Cx-Cy” when used in conjunction with a chemical moiety, such as alkyl, alkenyl, or alkynyl, is meant to include groups that contain from x to y carbons in the chain. For example, the term “Cx.yalkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, that contain from x to y carbons in the chain. As another example, the term “Co-e alkyl” encompasses both (a) a bond (i.e., when x is 0) and (b) substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, that contain from 1 to 6 carbons in the chain.
[0182]
[0026] “Alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including linear and branched alkyl groups. An alkyl group may contain from one to twelve carbon atoms (e.g., C1-12 alkyl), such as one to eight carbon atoms (C1-8 alkyl) or one to six carbon atoms (C1-6 alkyl). Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, and decyl. An alkyl group is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more substituents such as those substituents described herein.Attorney Docket No. 56690-815601
[0183]
[0027] “Haloalkyl” refers to an alkyl group that is substituted by one or more halogens. Exemplary haloalkyl groups include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, and 1,2-dibromoethyl.
[0184]
[0028] “Alkenyl” refers to substituted or unsubstituted hydrocarbon groups, including linear and branched alkenyl groups, containing at least one double bond. An alkenyl group may contain from two to twelve carbon atoms (e.g., C2-12 alkenyl), such as two to eight carbon atoms (C2-8 alkenyl) or two to six carbon atoms (C2-6 alkenyl). Exemplary alkenyl groups include ethenyl (i.e., vinyl), prop-l-enyl, but-l-enyl, pent-l-enyl, penta- 1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more substituents such as those substituents described herein.
[0185]
[0029] “Alkynyl” refers to substituted or unsubstituted hydrocarbon groups, including linear and branched alkynyl groups, containing at least one triple bond. An alkynyl group may contain from two to twelve carbon atoms (e.g., C2-12 alkynyl), such as two to eight carbon atoms (C2-8 alkynyl) or two to six carbon atoms (C2-6 alkynyl). Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more substituents such as those substituents described herein.
[0186]
[0030] “Alkylene” or “alkylene chain” refers to substituted or unsubstituted divalent saturated hydrocarbon groups, including linear alkylene and branched alkylene groups, that contain from one to twelve carbon atoms (e.g., C1-12 alkylene), such as one to eight carbon atoms (C1-8 alkylene) or one to six carbon atoms (C1-6 alkylene).
[0187] Exemplary alkylene groups include methylene, ethylene, propylene, and n-butylene. Similarly, “alkenylene” and “alkynylene” refer to alkylene groups, as defined above, which comprise one or more carbon-carbon double or triple bonds, respectively. The points of attachment of the alkylene, alkenylene or alkynylene chain to the rest of the molecule can be through one carbon or any two carbons of the chain. Unless stated otherwise specifically in the specification, an alkylene, alkenylene, or alkynylene group is optionally substituted by one or more substituents such as those substituents described herein.
[0188]
[0031] “Heteroalkyl”, “heteroalkenyl” and “heteroalkynyl” refer to substituted or unsubstituted alkyl, alkenyl and alkynyl groups, respectively, in which one or more, such as 1, 2 or 3, of the carbon atoms are replaced with a heteroatom, such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatoms may optionally be quaternized. If given, a numerical range refers to the chain length in total. For example, a 3- to 8-membered heteroalkyl group has a chain length of 3 to 8 atoms. Connection to the rest of the molecule may be through either a heteroatom or a carbon in the heteroalkyl, heteroalkenyl, or heteroalkynyl chain. Unless stated otherwise specifically in the specification, a heteroalkyl, heteroalkenyl, or heteroalkynyl group is optionally substituted by one or more substituents such as those substituents described herein.
[0189]
[0032] “Heteroalkylene”, “heteroalkenylene” and “heteroalkynylene” refer to substituted or unsubstituted alkylene, alkenylene and alkynylene groups, respectively, in which one or more, such as 1, 2 or 3, of the carbon atoms are replaced with a heteroatom, such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may optionally be oxidized, and any nitrogen heteroatoms may optionally be quaternized. If given, a numerical range refers to the chain length in total. For example, a 3 - to 8-membered heteroalkylene group has a chain length of 3 to 8 atoms. The points of attachment of the heteroalkylene, heteroalkenylene or heteroalkynylene chain to the rest of the molecule can be through either one heteroatom or one carbon, or any two heteroatoms, any two carbons, or any one heteroatom and any one carbon in the heteroalkylene,Attorney Docket No. 56690-815601
[0190] heteroalkenylene or heteroalkynylene chain. Unless stated otherwise specifically in the specification, a heteroalkylene, heteroalkenylene, or heteroalkynylene group is optionally substituted by one or more substituents such as those substituents described herein.
[0191]
[0033] “Carbocycle” refers to a saturated, unsaturated or aromatic ring in which each atom of the ring is a carbon atom. Carbocycle may include C3-10 monocyclic rings, C5-12 bicyclic rings, C5-18 polycyclic rings, C5-12 spirocyclic rings, and C5-12 bridged rings. Each ring of a bicyclic or polycyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. A polycyclic carbocycle contains a number or rings equal to the minimum number of scissions required to convert the carbocycle into an acyclic skeleton (e.g., bicyclic, tricyclic, tetracyclic, etc.). In some embodiments, the carbocycle is a Ce-i2 aryl group, such as Ce-io aryl. In some embodiments, the carbocycle is a C3-12 cycloalkyl group. In some embodiments, the carbocycle is a C5-12 cycloalkenyl group. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic rings, as valence permits, are included in the definition of carbocycle. A carbocycle may comprise a fused ring, a bridged ring, a spirocyclic ring, a saturated ring, an unsaturated ring, an aromatic ring, or any combination thereof. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantly, phenyl, indanyl, and naphthyl. Unless state otherwise specifically in the specification, a carbocycle is optionally substituted by one or more substituents such as those substituents described herein.
[0192]
[0034] “Heterocycle” refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms, for example 1, 2, 3, or 4 heteroatoms selected from O, S, P, and N. Heterocycle may include 3- to 10-membered monocyclic rings, 5- to 12-membered bicyclic rings, 5- to 18-membered polycyclic rings, 5- to 12-membered spirocyclic rings, and 5- to 12-membered bridged rings. Each ring of a bicyclic or polycyclic heterocycle may be selected from saturated, unsaturated, and aromatic rings. A polycyclic heterocycle contains a number or rings equal to the minimum number of scissions required to convert the heterocycle into an acyclic skeleton (e.g., bicyclic, tricyclic, tetracyclic, etc.). The heterocycle may be attached to the rest of the molecule through any atom of the heterocycle, valence permitting, such as a carbon or nitrogen atom of the heterocycle. In some embodiments, the heterocycle is a 5- to 10-membered heteroaryl group, such as 5- or 6-membered heteroaryl. In some embodiments, the heterocycle is a 3- to 12-membered heterocycloalkyl group. A heterocycle may comprise a fused ring, a bridged ring, a spirocyclic ring, a saturated ring, an unsaturated ring, an aromatic ring, or any combination thereof. In an exemplary embodiment, a heterocycle, e.g., pyridyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl, benzothienyl, benzoxazolyl, and quinolinyl. Unless stated otherwise specifically in the specification, a heterocycle is optionally substituted by one or more substituents such as those substituents described herein.
[0193]
[0035] “Heteroaryl” refers to an aromatic ring that comprises at least one heteroatom, for example 1, 2, 3, or 4 heteroatoms selected from O, S and N. Heteroaryl may include 5- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 6- to 18-membered polycyclic rings, 5- to 12-membered spirocyclic rings, and 6- to 12-membered bridged rings. As used herein, the heteroaryl ring may be selected from monocyclic, bicyclic, or polycyclic — including fused, spirocyclic and bridged ring systems — wherein at least one of the rings in the ring system is aromatic and comprises at least one heteroatom. A polycyclic heteroaryl contains a number or rings equal to the minimum number of scissions required to convert the heteroaryl into an acyclic skeleton (e.g., bicyclic,Attorney Docket No. 56690-815601
[0194] tricyclic, tetracyclic, etc.). The heteroatom(s) in the heteroaryl may optionally be oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl may be attached to the rest of the molecule through any atom of the heteroaryl, valence permitting, such as a carbon or nitrogen atom of the heteroaryl. Examples of heteroaryl groups include, but are not limited to, azepinyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroquinolinyl, thiadiazolyl, thiazolyl, and thienyl groups. Unless stated otherwise specifically in the specification, a heteroaryl is optionally substituted by one or more substituents such as those substituents described herein.
[0195]
[0036] Unless stated otherwise, hydrogen atoms are implied in structures depicted herein as necessary to satisfy the valence requirement.
[0196]
[0037] A waved line “ ” drawn across or at the end of a bond or a dashed bond “ - - ' ” are used interchangeably
[0197]
[0198] herein to denote where a bond disconnection or attachment occurs. For example, in the structurerB7
[0199] RB7is 2-fluoro-6-hydroxyphenyl
[0200]
[0201]
[0202]
[0038] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons or heteroatoms of the structure. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, heteroatoms such as nitrogen may have any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
[0203]
[0039] In some embodiments, a moiety substituted with one or more substituents is substituted with one, two, three, four, or five substituents. In some embodiments, a moiety substituted with one or more substituents is substituted with one, two, three, or four substituents. In some embodiments, a moiety substituted with one or more substituents is substituted with one, two, or three substituents. A moiety described herein that is optionally substituted with one or more substituents can be unsubstituted or substituted with one, two, three, four, or five substituents. In some embodiments, a moiety optionally substituted with one or more substituents is unsubstituted or substituted with one, two, three, or four substituents. In some embodiments, a moiety optionally substituted with one or more substituents is unsubstituted or substituted with one, two, or three substituents.
[0204]
[0040] A compound disclosed herein, such as a compound of Formula (A0), (A0-1), (AO-2), (A0-3), (aO), (a0-l), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), is optionally substitutedAttorney Docket No. 56690-815601
[0205] by one or more — such as 1, 2 or 3 — substituents selected from:
[0206] halogen, oxo, -CN, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two substituents attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0207] RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0208] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein -Co-6 alkyl-(C3-i2 carbocycle) and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three groups independently selected from halogen and C1-6 alkyl; and
[0209] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle.
[0210]
[0041] In some embodiments, a compound disclosed herein, such as a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), is optionally substituted by one or more — such as 1, 2 or 3 — substituents selected from:
[0211] halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, and -S(O)2N(RB22)(RB23)-, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- toAttorney Docket No. 56690-815601
[0212] 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, and =C(RB21)2;
[0213] RB21is independently selected at each occurrence from hydrogen, halogen, Ci-6 alkyl, and Ci-6 haloalkyl; RB22is independently selected at each occurrence from hydrogen, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2. e alkynyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein -Co-6 alkyl-(C3-i2carbocycle) and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three groups independently selected from halogen and Ci-6 alkyl;
[0214] RB23is independently selected at each occurrence from hydrogen and Ci-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle.
[0215]
[0042] In some embodiments, a compound disclosed herein, such as a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), is optionally substituted by one or more — such as 1, 2 or 3 — substituents selected from halogen, oxo, =NH, -CN, -NO2, CI-6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, -CH2-(C3-IO carbocycle), 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, wherein Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocycle, -CH2-(C3-IO carbocycle), 3- to 10-membered heterocycle, and -CH2-(3- to 10-membered heterocycle) are optionally substituted with one, two, or three groups independently selected from halogen, oxo, =NH, -CN, -NO2, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3.
[0216]
[0043] It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate. Unless specifically stated as “unsubstituted”, references to chemical moieties herein are understood to include substituted variants. For example, reference to a “heteroaryl” group or moiety implicitly includes both substituted and unsubstituted variants.
[0217]
[0044] Where bivalent substituent groups are specified herein by their conventional chemical formulae, written from left to right, they are intended to encompass the isomer that would result from writing the structure from right to left, e.g., -CH2O- is also intended to encompass -OCH2-.
[0218]
[0045] “Optional” or “optionally” means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, an “optionally substituted” group may be either unsubstituted or substituted.
[0219]
[0046] Compounds of the present disclosure also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, amorphous forms of the compounds, and mixtures thereof.
[0220]
[0047] The compounds described herein may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure. For example, hydrogen has three naturally occurring isotopes, denoted1H (protium),2H (deuterium), and3H (tritium). Protium is the most abundant isotope of hydrogen in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increased in vivo half-life and / or exposure, or may provide a compound useful for investigating in vivo routes of drug elimination and metabolism. Examples of isotopes that may be incorporated intoAttorney Docket No. 56690-815601
[0221] compounds of the present disclosure include, but are not limited to,2H,3H,13C,14C,15N,180,170,35S,36C1, and18F. Of particular interest are compounds of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8) enriched in tritium or carbon-14, which can be used, for example, in tissue distribution studies; compounds of the disclosure enriched in deuterium — especially at a site of metabolism — resulting, for example, in compounds having greater metabolic stability; and compounds of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8) enriched in a positron emitting isotope, such asnC,18F,15O and13N, which can be used, for example, in Positron Emission Topography (PET) studies. Isotopically -enriched compounds may be prepared by conventional techniques well known to those skilled in the art.
[0222]
[0048] As used herein, the phrase “of the formula”, “having the formula” or “having the structure” is not intended to be limiting and is used in the same way that the term “comprising” is commonly used. For example, if one structure is depicted, it is understood that all stereoisomer and tautomer forms are encompassed, unless stated otherwise.
[0223]
[0049] Certain compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, the asymmetric centers of which can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. In some embodiments, in order to optimize the therapeutic activity of the compounds of the disclosure, e.g., to treat cancer, it may be desirable that the carbon atoms have a particular configuration (e.g., (R, R), (S, S), (S, R), or (R, S)) or are enriched in a stereoisomeric form having such configuration. The compounds of the disclosure may be provided as racemic mixtures. Accordingly, the disclosure relates to racemic mixtures, pure stereoisomers (e.g., enantiomers and diastereomers), stereoisomer-enriched mixtures, and the like, unless otherwise indicated. When a chemical structure is depicted herein without any stereochemistry, it is understood that all possible stereoisomers are encompassed by such structure. Similarly, when a particular stereoisomer is shown or named herein, it will be understood by those skilled in the art that minor amounts of other stereoisomers may be present in the compositions of the disclosure unless otherwise indicated, provided that the utility of the composition as a whole is not eliminated by the presence of such other isomers. Individual stereoisomers may be obtained by numerous methods that are known in the art, including preparation using chiral synthons or chiral reagents, resolution using chiral chromatography using a suitable chiral stationary phase or support, or by chemically converting them into diastereomers, separating the diastereoisomers by conventional means such as chromatography or recrystallization, then regenerating the original stereoisomer.
[0224]
[0050] Additionally, where applicable, all cis-trans or E / Z isomers (geometric isomers), tautomeric forms and topoisomeric forms of the compounds described herein are included with the scope of the disclosure unless otherwise specified.
[0225]
[0051] The term “pharmaceutically acceptable” refers to a material that is not biologically or otherwise unacceptable when used in the subject compositions and methods. For example, the term “pharmaceutically acceptable carrier” refers to a material — such as an adjuvant, excipient, glidant, sweetening agent, diluent, preservative, dye, colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent or emulsifier — that can be incorporated into a composition and administered to a patient without causing unacceptable biological effects or interacting in an unacceptable manner with other components of the composition. Such pharmaceutically acceptable materials typically have met the required standards of toxicological and manufacturing testing, and include those materials identified as suitable inactive ingredients by the U. S. Food and Drug Administration.Attorney Docket No. 56690-815601
[0226]
[0052] The terms “salt” and “pharmaceutically acceptable salt” refer to a salt prepared from a base or an acid. Pharmaceutically acceptable salts are suitable for administration to a patient, such as a mammal (for example, salts having acceptable mammalian safety for a given dosage regime). Salts can be formed from inorganic bases, organic bases, inorganic acids and organic acids. In addition, when a compound contains both a basic moiety, such as an amine, pyridine or imidazole, and an acidic moiety, such as a carboxylic acid or tetrazole, zwitterions may be formed and are included within the term “salt” as used herein. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0227]
[0053] “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc., and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Also contemplated are salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S. M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
[0228]
[0054] “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. See Berge et al., supra.
[0229]
[0055] The term “effective amount” or “therapeutically effective amount” refers to the amount of an agent that is sufficient to effect beneficial or desired results. The therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinaryAttorney Docket No. 56690-815601
[0230] skill in the art. An effective amount of an active agent may be administered in a single dose or in multiple doses. A component may be described herein as having at least an effective amount, or at least an amount effective, such as that associated with a particular goal or purpose, such as any described herein. The term “effective amount” also applies to a dose that will provide an image for detection by an appropriate imaging method. The specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
[0231]
[0056] As used herein, “treating” or “treatment” refers to an approach for obtaining beneficial or desired results with respect to a disease, disorder, or medical condition (such as cancer) in a subject, including but not limited to the following: (a) ameliorating the disease or medical condition, e.g., eliminating or causing regression of the disease or medical condition in a subject; (b) suppressing the disease or medical condition, e.g., slowing or arresting the development of the disease or medical condition in a subject; or (c) alleviating symptoms of the disease or medical condition in a subject. For example, “treating cancer” would include preventing cancer from reoccurring, ameliorating cancer, suppressing cancer, and alleviating the symptoms of cancer. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder.
[0232]
[0057] A “therapeutic effect”, as that term is used herein, encompasses a therapeutic benefit and / or prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
[0233]
[0058] The terms “antagonist” and “inhibitor” are used interchangeably, and they refer to a compound having the ability to inhibit a biological function (e.g., activity, expression, binding, protein-protein interaction) of a target protein (e.g., K-Ras). Accordingly, the terms “antagonist” and “inhibitor” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g., bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition.
[0234]
[0059] The term “selective inhibition” or “selectively inhibit” refers to the ability of a biologically active agent to preferentially reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.
[0235]
[0060] The terms “subject” and “patient” refer to an animal, such as a mammal, for example a human. The methods described herein can be useful in both human therapeutics and veterinary applications. In some embodiments, the subject is a mammal, such as a human. “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and nondomestic animals such as wildlife and the like.
[0236]
[0061] The terms “therapeutic agent”, “therapeutic capable agent” or “treatment agent” are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. The beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.
[0237]
[0062] The terms “polypeptide”, “peptide” and “protein” are used interchangeably herein to refer to polymers ofAttorney Docket No. 56690-815601
[0238] amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term “amino acid” refers to either natural and / or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
[0239]
[0063] The terms “polynucleotide”, “nucleotide sequence”, “nucleic acid” and “oligonucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or noncoding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs, such as peptide nucleic acid (PNA), morpholino and locked nucleic acid (LNA), glycol nucleic acid (GNA), threose nucleic acid (TNA), 2 ’-fluoro, 2’-OMe, and phosphorothiolated DNA. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component or other conjugation target.
[0240]
[0064] As used herein, “expression” refers to the process by which a polynucleotide is transcribed from a DNA template (such as into an mRNA or other RNA transcript) and / or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as “gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
[0241]
[0065] An “antigen” is a moiety or molecule that contains an epitope, and, as such, also specifically binds to an antibody. An “antigen binding unit” may be whole or a fragment (or fragments) of a full-length antibody, a structural variant thereof, a functional variant thereof, or a combination thereof. A full-length antibody may be, for example, a monoclonal, recombinant, chimeric, deimmunized, humanized and human antibody. Examples of a fragment of a full-length antibody may include, but are not limited to, variable heavy (VH), variable light (VL), a heavy chain found in camelids, such as camels, llamas, and alpacas (VHH or VHH), a heavy chain found in sharks (V-NAR domain), a single domain antibody (sdAb, e.g., “nanobody”) that comprises a single antigen-binding domain, Fv, Fd, Fab, Fab', F(ab')2, and “r IgG” (or half antibody). Examples of modified fragments of antibodies may include, but are not limited to scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, minibodies (e.g., (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2), and multibodies (e.g., triabodies or tetrabodies).
[0242]
[0066] The term “antibody” and “antibodies” encompass any antigen binding units, including without limitation: monoclonal antibodies, human antibodies, humanized antibodies, camelised antibodies, chimeric antibodies, and any other epitope-binding fragments.
[0243]
[0067] “Prodrug” is meant to indicate a compound that may be converted under physiological conditions or byAttorney Docket No. 56690-815601
[0244] solvolysis to a biologically active compound described herein (e.g., a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)). Thus, the term “prodrug” refers to a precursor of a biologically active compound that is pharmaceutically acceptable. In some aspects, a prodrug is inactive when administered to a subject but is converted in vivo to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp.
[0245] 7-9, 21-24 (Elsevier, Amsterdam); Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” (1987) A. C. S. Symposium Series, Vol. 14; and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press each of which is incorporated in full by reference herein). The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. Prodrugs of an active compound, as described herein, are typically prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound, and the like.
[0246]
[0068] The term “in vivo” refers to an event that takes place in a subject’s body. The term “ex vivo” refers to an event that first takes place outside of the subject’s body for a subsequent in vivo application into a subject’s body. For example, an ex vivo preparation may involve preparation of cells outside of a subject’s body for the purpose of introduction of the prepared cells into the same or a different subject’s body. The term “in vitro” refers to an event that takes place outside of a subject’s body. For example, an in vitro assay encompasses any assay run outside of a subject’s body. In vitro assays encompass cell-based assays in which cells alive or dead are employed. In vitro assays also encompass a cell-free assay in which no intact cells are employed.
[0247]
[0069] The disclosure is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the disclosure includes compounds produced by a process comprising administering a compound disclosed herein to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabeled compound of the disclosure in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to a human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
[0248]
[0070] The term “Ras” or “RAS” refers to a protein in the Rat sarcoma (Ras) superfamily of small GTPases, such as in the Ras subfamily. The Ras superfamily includes, but is not limited to, the Ras subfamily, Rho subfamily, Rab subfamily, Rap subfamily, Arf subfamily, Ran subfamily, Rheb subfamily, RGK subfamily, Rit subfamily, Miro subfamily, and Unclassified subfamily. In some embodiments, a Ras protein is selected from the group consisting of KRAS (also used interchangeably herein as K-Ras, K-ras, or Kras), HRAS (or H-Ras), NRAS (or N-Ras), MRAS (or M-Ras), ERAS (or E-Ras), RRAS2 (or R-Ras2), RALA (or RalA), RALB (or RalB), RIT1, and any combination thereof, such as from KRAS, HRAS, NRAS, RALA, RALB, and any combination thereof.
[0249]
[0071] The terms “mutant Ras” and “Ras mutant”, as used interchangeably herein, refer to a Ras protein with oneAttorney Docket No. 56690-815601
[0250] or more amino acid mutations, such as with respect to a common reference sequence such as a wild-type (WT) sequence. In some embodiments, a mutant Ras is selected from a mutant KRAS, mutant HRAS, mutant NRAS, mutant MRAS, mutant ERAS, mutant RRAS2, mutant RALA, mutant RALB, mutant RIT1, and any combination thereof, such as from a mutant KRAS, mutant HRAS, mutant NRAS, mutant RALA, mutant RALB, and any combination thereof. In some embodiments, a mutation can be an introduced mutation, a naturally occurring mutation, or a non-naturally occurring mutation. In some embodiments, a mutation can be a substitution (e.g., a substituted amino acid), insertion (e.g., addition of one or more amino acids), or deletion (e.g., removal of one or more amino acids). In some embodiments, two or more mutations can be consecutive, non-consecutive, or a combination thereof. In some embodiments, a mutation can be present at any position of Ras. In some embodiments, a mutation can be present at position 12, 13, 62, 92, 95, 96 (e.g., Y96D), or any combination thereof of Ras relative to SEQ ID No. 1 when optimally aligned. In some embodiments, a mutant Ras may comprise about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more than 50 mutations. In some embodiments, a mutant Ras may comprise up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 mutations. In some embodiments, the mutant Ras is about or up to about 500, 400, 300, 250, 240, 233, 230, 220, 219, 210, 208, 206, 204, 200, 195, 190, 189, 188, 187, 186, 185, 180, 175, 174, 173, 172, 171, 170, 169, 168, 167, 166, 165, 160, 155, 150, 125, 100, 90, 80, 70, 60, 50, or fewer than 50 amino acids in length. In some embodiments, an amino acid of a mutation is a proteinogenic, natural, standard, non-standard, non-canonical, essential, non-essential, or non-natural amino acid. In some embodiments, an amino acid of a mutation has a positively charged side chain, a negatively charged side chain, a polar uncharged side chain, a non-polar side chain, a hydrophobic side chain, a hydrophilic side chain, an aliphatic side chain, an aromatic side chain, a cyclic side chain, an acyclic side chain, a basic side chain, or an acidic side chain. In some embodiments, a mutation comprises a reactive moiety. In some embodiments, a substituted amino acid comprises a reactive moiety. In some embodiments, a mutant Ras can be further modified, such as by conjugation with a detectable label. In some embodiments, a mutant Ras is a full-length or truncated polypeptide. For example, a mutant Ras can be a truncated polypeptide comprising residues 1-169 or residues 11-183 (e.g., residues 11-183 of a mutant RALA or mutant RALB).
[0251]
[0072] As used herein, the term “corresponding to” or “corresponds to” as applied to an amino acid residue in a polypeptide sequence refers to the correspondence of such amino acid relative to a reference sequence when optimally aligned (e.g., taking into consideration of gaps, insertions and mismatches; wherein alignment may be primary sequence alignment or three-dimensional structural alignment of the folded proteins). For instance, the serine residue in a K-Ras G12S mutant refers to the serine corresponding to residue 12 of SEQ ID No. 4, which can serve as a reference sequence. For instance, the aspartate residue in a K-Ras G12D mutant refers to the aspartate corresponding to residue 12 of SEQ ID No. 2, which can serve as a reference sequence. When an amino acid of a mutant Ras protein corresponds to an amino acid position in the WT Ras protein, it will be understood that although the mutant Ras protein amino acid may be a different amino acid (e.g., G12D, wherein the wildtype G at position 12 is replaced by an aspartate at position 12 of SEQ ID. No. 1), the mutant amino acid is at the position corresponding to the wildtype amino acid (e.g., of SEQ ID No. 1). In embodiments, a modified Ras mutant protein disclosed herein may comprise truncations at the C-terminus, or truncations at the N-terminal end preceding the serine residue. The serine residue in such N-terminal truncated modified mutant is still considered corresponding to position 12 of SEQ ID No. 1. In addition, an aspartate residue at position 12 of SEQ ID No. 2 finds a corresponding residue in SEQ ID Nos. 6 and 8.Attomey Docket No. 56690-815601
[0252]
[0073] A “degradation enhancer” is a compound capable of binding a ubiquitin ligase protein (e.g., E3 ubiquitin ligase protein) or a compound capable of binding a protein that is capable of binding to a ubiquitin ligase protein to form a protein complex capable of conjugating a ubiquitin protein to a target protein. In some embodiments, the degradation enhancer is capable of binding to an E3 ubiquitin ligase protein or a protein complex comprising an E3 ubiquitin ligase protein. In some embodiments, the degradation enhancer is capable of binding to an E2 ubiquitin-conjugating enzyme. In some embodiments, the degradation enhancer is capable of binding to a protein complex comprising an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase protein.
[0253] Methods of Preparing Degrader Compounds
[0254]
[0074] In an aspect is provided a method of preparing a compound of Formula (AO):
[0255]
[0256] the method comprising:
[0257] (a) reacting a compound of Formula (aO):
[0258]
[0259] with a degradation enhancer under conditions to effect release of LG and production of the compound of Formula (AO), wherein:
[0260] Z1is selected from N and N(RBlb);
[0261] Z2is selected from C(RB2) and C(O);
[0262] ZB5is selected from C(RB9)2 and O;
[0263] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0264] Z7is selected from C(RB7) and N(RB7b);
[0265] Z8is selected from C(RB8), C(RB8)2, and N;
[0266] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0267] J1is selected from a bond, Ci-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0268] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-Attorney Docket No. 56690-815601
[0269] , -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB20;
[0270] J3is selected from Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;
[0271] DG is a degradation enhancer;
[0272] LG is a leaving group;
[0273] nl is selected from 1, 2, and 3;
[0274] RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0275] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0276] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0277] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0278] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0279] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23),Attomey Docket No. 56690-815601
[0280] =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atoms optionally join to form C3-12carbocycle or 3- to 12-membered heterocycle; wherein Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -C0-6 alkyl-(C3-12 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -C0-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0281] RB21is independently selected at each occurrence from hydrogen, halogen, Ci-6 alkyl, Ci-6 haloalkyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0282] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0283] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0284] indicates a single or double bond such that all valences are satisfied.
[0285]
[0075] In an aspect is provided a method of preparing a compound of Formula (A):
[0286]
[0287] the method comprising:
[0288] (a) reacting a compound of Formula (a):
[0289]
[0290] with a degradation enhancer under conditions to effect release of LG and production of the compound of Formula (A), wherein:
[0291] Z1is selected from N and N(RBlb);Attomey Docket No. 56690-815601
[0292] Z2is selected from C(RB2) and C(O);
[0293] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0294] Z7is selected from C(RB7) and N(RB7b);
[0295] Z8is selected from C(RB8), C(RB8)2, and N;
[0296] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0297] J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0298] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB2°;
[0299] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°;
[0300] DG is a degradation enhancer;
[0301] LG is a leaving group;
[0302] nl is selected from 1, 2, and 3;
[0303] RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0304] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-Attorney Docket No. 56690-815601
[0305] membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;
[0306] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0307] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0308] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0309] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0310] RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0311] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0312] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0313] indicates a single or double bond such that all valences are satisfied.
[0314]
[0076] In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the reaction mixture comprises a base. In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the reactionAttomey Docket No. 56690-815601
[0315] mixture comprises 5- to 12 -equivalents of the base relative to the amount of degradation enhancer. In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the base is N,N-diisopropylethylamine. In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the compound of Formula (AO) and / or (A) and the degradation enhancer are heated to 40 to 100 °C for 2 to 48 hours. In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the method further comprises (b) purifying the compound of Formula (AO) and / or (A). In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the method may include the preparation of any embodiment of the compound of Formula (AO) and / or (A), including preparation of a compound of Formula (AO-1), (AO-2), (AO-3), (A-l), (A-2), or (A-3), or any embodiment thereof. In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the method may include the use of any embodiment of the compound of Formula (AO) and / or (A) including the use of a compound of Formula (aO-1), (aO-2), (a0-3), (a-l), (a-2), or (a-3), or any embodiment thereof.
[0316]
[0077] In embodiments of the method of preparing a compound of Formula (AO) and / or (A), the degradation
[0317]
[0318] J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, Ci-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3-to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O). In embodiments of the method of preparing a compound of Formula (A0) and / or (A), DG is selected from
[0319]
[0320] 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O). In embodiments of the method of preparing a compound of Formula (A0) and / or (A), LG is selected from -Cl, -Br, -I, -OBt, -OS(O)2RB4and -OS(O)(NRB4b)RB4; RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-Attorney Docket No. 56690-815601
[0321] membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), and -N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°; RB4bis selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°; and RB12)(RB13), and RB2° are as described for a compound of Formula (AO) and / or (A) or embodiments thereof. The term “-OBt” is -O-benzotriazole.
[0322]
[0078] In some embodiments of the method of preparing a compound of Formula (AO) or (A), RB2is selected from: (i) -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein C1-6 alkyl, C3-4 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, Ci-6 alkyl, and Ci-6 haloalkyl; RB22is independently selected at each occurrence from hydrogen, Ci-6 alkyl, Ci-6 haloalkyl, C3-4 carbocycle, and 3- to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and Ci-e alkyl; (ii) -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein the (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle; (iii) -O(C2-3 alkylene)(pyrrolidine), wherein the pyrrolidine is substituted with two or three substituents independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2; (iv) -O(Ci-3alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms) optionally substituted with one unsubstituted C1-3 alkyl; and (v) -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(8- to 10-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence from hydrogen and halogen.
[0323]
[0079] In some embodiments, a method of preparing a compound of Formula (A) may further comprise:
[0324] (b) reacting a compound of the formulaAttomey Docket No. 56690-815601
[0325]
[0326] with a suitable electrophile (e.g., CH3CH2SO2CI) under conditions to effect formation of LG and production of the compound of Formula (a). In some embodiments, the method may further comprise:
[0327] (c) reacting a compound of the formula
[0328]
[0329] under conditions suitable for selectively removing protecting group PG (e.g., PdCL and H2when PG is Bn), thereby forming the corresponding alcohol.
[0330] Compounds
[0331]
[0080] In an aspect is provided a compound of Formula (AO):
[0332]
[0333] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0334] Z1is selected from N and N(RBlb);
[0335] Z2is selected from C(RB2) and C(O);
[0336] ZB5is selected from C(RB9)2 and O;
[0337] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0338] Z7is selected from C(RB7) and N(RB7b);
[0339] Z8is selected from C(RB8), C(RB8)2, and N;
[0340] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0341] J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0342] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalky l)-(3- to 12-Attorney Docket No. 56690-815601
[0343] membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB20;
[0344] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;
[0345] DG is a degradation enhancer;
[0346] nl is selected from 1, 2, and 3;
[0347] RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0348] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0349] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0350] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0351] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0352] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23),Attorney Docket No. 56690-815601
[0353] =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atoms optionally join to form C3-12carbocycle or 3- to 12-membered heterocycle; wherein Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -C0-6 alkyl-(C3-12 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -C0-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0354] RB21is independently selected at each occurrence from hydrogen, halogen, Ci-6 alkyl, Ci-6 haloalkyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0355] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0356] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0357] indicates a single or double bond such that all valences are satisfied.
[0358]
[0081] In an aspect is provided a compound of Formula (A):
[0359]
[0360] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0361] Z1is selected from N and N(RBlb);
[0362] Z2is selected from C(RB2) and C(O);
[0363] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0364] Z7is selected from C(RB7) and N(RB7b);
[0365] Z8is selected from C(RB8), C(RB8)2, and N;
[0366] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0367] J1is selected from a bond, C1-6 alkylene, C2-6alkenylene, C2-6alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -Attorney Docket No. 56690-815601
[0368] P(O)RB12O-, wherein Ci-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0369] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB20;
[0370] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;
[0371] DG is a degradation enhancer;
[0372] nl is selected from 1, 2, and 3;
[0373] RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0374] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0375] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0376] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0377] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one orAttorney Docket No. 56690-815601
[0378] more RB20;
[0379] RB20is independently selected at each occurrence from halogen, oxo, -CN, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0380] RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0381] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0382] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0383] > indicates a single or double bond such that all valences are satisfied.
[0384]
[0082] In embodiments of a compound described herein (e.g., compound of Formula (AO) and / or (A)), or a salt or solvate thereof, the degradation enhancer is capable of binding a protein selected from E3A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperon-mediated autophage), SCFb-TRCP (Skip-Cullin-F box (Beta-TRCP) ubiquitin complex), b-TRCP (b -transducing repeat-containing protein), cIAPl (cellular inhibitor of apoptosis protein 1), APC / C (anaphase-promoting complex / cyclosome), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, iberdomide, and CC-885.Attorney Docket No. 56690-815601
[0385]
[0083] In embodiments of a compound described herein (e.g., compound of Formula (AO) and / or (A)), or a salt or solvate thereof, the degradation enhancer is capable of binding a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1.
[0386]
[0084] In embodiments of a compound described herein (e.g., compound of Formula (AO) and / or (A)), or a salt or
[0387] solvate thereof, DG is selected from:
[0388]
[0389] wherein: J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3-to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, Ci-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O).
[0390]
[0085] In embodiments of a compound described herein (e.g., compound of Formula (A0) and / or (A)), or a salt or
[0391]
[0392] wherein: J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3-to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from -CH(CH3)2 and -C(CH3)3; RB16is selected from hydrogen, -CH3, and -CH2OH; RB17is selected from methylthiazole and methylpyrazole; ol is selected from 0 and 1; pl and ql are independently selected from 1 and 2; and X is selected from CH2and C(O).
[0393]
[0086] In embodiments of a compound described herein (e.g., compound of Formula (AO) and / or (A)), or a salt or
[0394] solvate thereof, DG is selected from:
[0395]
[0396] Attorney Docket No. 56690-815601
[0397]
[0398]
[0087] In embodiments of a compound described herein (e.g., compound of Formula (AO) and / or (A)), or a salt or
[0399]
[0400]
[0088] In embodiments of a compound described herein (e.g., compound of Formula (AO) and / or (A)), or a salt or
[0401]
[0402] Attorney Docket No. 56690-815601
[0403]
[0404] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0405] Z1is selected from N and N(RBlb);
[0406] Z2is selected from C(RB2) and C(O);
[0407] ZB5is selected from C(RB9)2 and O;
[0408] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0409] Z7is selected from C(RB7) and N(RB7b);
[0410] Z8is selected from C(RB8), C(RB8)2, and N;
[0411] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0412] J1is selected from a bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0413] J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB20;
[0414] J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- toAttorney Docket No. 56690-815601
[0415] 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;
[0416] LG is selected from -OS(O)2RB4and -OS(O)(NRB4b)RB4;
[0417] nl is selected from 1, 2, and 3;
[0418] RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), and -N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0419] RBlb, RB4b, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0420] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0421] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0422] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0423] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0424] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6Attorney Docket No. 56690-815601
[0425] alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0426] RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0427] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0428] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0429] > indicates a single or double bond such that all valences are satisfied.
[0430]
[0090] In an aspect is provided a compound of Formula (a):
[0431]
[0432] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0433] Z1is selected from N and N(RBlb);
[0434] Z2is selected from C(RB2) and C(O);
[0435] Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);
[0436] Z7is selected from C(RB7) and N(RB7b);
[0437] Z8is selected from C(RB8), C(RB8)2, and N;
[0438] Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;
[0439] J1is selected from a bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -Attorney Docket No. 56690-815601
[0440] N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein Ci-6 alkylene, C2-6alkenylene, C2-6alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;
[0441] J2is selected from a bond, -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB20;
[0442] J3is selected from Ci-6 alkylene, C2-6alkenylene, C2-6alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;
[0443] LG is selected from -OS(O)2RB4and -OS(O)(NRB4b)RB4;
[0444] nl is selected from 1, 2, and 3;
[0445] RB4is selected from Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), and -N(RB12)(RB13), wherein Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0446] RBlb, RB4b, RB6b, and RB7bare independently selected from hydrogen, -CN, Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;
[0447] RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) areAttorney Docket No. 56690-815601
[0448] optionally substituted with one or more RB20;
[0449] RB9is independently selected at each occurrence from hydrogen and RB2°;
[0450] RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;
[0451] RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;
[0452] RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);
[0453] RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;
[0454] RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);
[0455] RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; and
[0456] indicates a single or double bond such that all valences are satisfied.
[0457]
[0091] In embodiments of a compound described herein (e.g., compound of Formula (aO) and / or (a)), or a salt or solvate thereof, LG is -OS(O)2RB4.
[0458]
[0092] In embodiments of a compound described herein (e.g., compound of Formula (AO), (A), (aO), and / or (a)), or a salt or solvate thereof, nl is 1. In embodiments, nl is 2. In embodiments, nl is 3. In embodiments of aAttorney Docket No. 56690-815601
[0459] compound described herein (e.g., compound of Formula (AO), (A), (aO), and / or (a)), or a salt or solvate thereof, Q2is 7- to 9-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB2° In embodiments of a compound described herein (e.g., compound of Formula (AO), (A), (aO), and / or (a)), or a salt or solvate thereof, - A
[0460] I '' r
[0461] is i, each of which is optionally substituted with one or more RB20.
[0462]
[0093] In embodiments of a compound described herein (e.g., compound of Formula (AO), (A), (aO), and / or (a)), or a salt or solvate thereof, Z1is N, Z2is C(RB2), Z6is C(RB6), Z7is C(RB7), and Z8is C(RB8); Z1is N, Z2is C(RB2), Z6is N, Z7is C(RB7), and Z8is C(RB8); Z1is N, Z2is C(RB2), Z6is C(RB6)2, Z7is N(RB7b), and Z8is C(RB8)2; or Z1is N(RBlb), Z2is C(O), Z6is C(RB6), Z7is C(RB7), and Z8is N. In embodiments of a compound described herein (e.g., compound of Formula (a)), or a salt or solvate thereof, Z1is N, Z2is C(RB2), Z6is C(RB6), Z7is C(RB7), and Z8is C(RB8). In embodiments of a compound described herein (e.g., compound of Formula (a)), or a salt or solvate thereof, Z1is N, Z2is C(RB2), Z6is N, Z7is C(RB7), and Z8is C(RB8).
[0463]
[0094] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, J1is selected from a bond, Ci-6 alkylene, 2- to 6-membered heteroalkylene, and -C(O)-, wherein Ci-6 alkylene and 2- to 6-membered heteroalkylene are optionally substituted with one or more RB2°. In embodiments, J1is -C(O)-. In embodiments, J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, and -Co-6 alkyl-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2carbocycle)- and -Co-6 alkyl-(3- to 12-membered heterocycle)-are optionally substituted with one or more RB2°. In embodiments, J2is a bond. In embodiments, J3is selected from Ci-6 alkylene, 2- to 6-membered heteroalkylene, -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-i2carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°. In embodiments, J3is selected from Ci-6 alkylene and 2- to 6-membered heteroalkylene, each of which is optionally substituted with one or more RB2°. In embodiments, J3is selected from Ci-6 alkylene and 2- to 6-membered heteroalkylene. In embodiments, J3is selected from -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-i2carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°.
[0464]
[0095] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, J1is -C(O)-; J2is a bond; and J3is Ci-6 alkylene. In embodiments, J1is a bond; J2is a bond; and J3is selected from Ci-6 alkylene and 2- to 6-membered heteroalkylene, each of which is optionally substituted with one or more RB2°. In embodiments, J1is -C(O)-; J2is 3- to 12-membered heterocycle optionally substituted with one or more RB2°; and J3is Ci-6 alkylene.
[0465]
[0096] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is selected from: (i) -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22;Attorney Docket No. 56690-815601
[0466] wherein Ci-6 alkyl, C3-4 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, Ci-e alkyl, and C1-6 haloalkyl; RB22is independently selected at each occurrence from hydrogen, Ci-e alkyl, C1-6 haloalkyl, C3-4 carbocycle, and 3- to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and Ci-e alkyl; (ii) -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein the (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle; (iii) -O(C2-3 alkylene)(pyrrolidine), wherein the pyrrolidine is substituted with two or three substituents independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2; (iv) -O(Ci-3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms) optionally substituted with one unsubstituted C1-3 alkyl; and (v) -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene) -(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence from hydrogen and halogen. In some embodiments, RB2is -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein C1-6 alkyl, C3-4 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, and C1-6 haloalkyl; RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-4 carbocycle, and 3- to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In some embodiments, RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein the (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle. In some embodiments, RB2is -O(C2-3 alkylene)(pyrrolidine), wherein the pyrrolidine is substituted with two or three substituents independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2. In some embodiments, RB2is -O(Ci.3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms) optionally substituted with one unsubstituted C1-3 alkyl. In some embodiments, RB2is -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence from hydrogen and halogen.
[0467]
[0097] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3),Attorney Docket No. 56690-815601
[0468] (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci-3 alkylene)(4- to 10-membered heterocycle), wherein 4- to 10-membered heterocycle is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, -C0-1 alkyl-(C3-4 carbocycle) optionally substituted with one or more halogen, 4- to 8-membered heterocycle, -(2- to 3-membered heteroalkyl)-( C3-4 carbocycle) optionally substituted with one or more substituents selected from oxo and C1-3 alkyl, and =C(RB21)2, wherein RB21is independently selected at each occurrence from hydrogen, halogen, CN,
[0469]
[0470]
[0098] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or
[0471] solvate thereof,
[0472]
[0473] wherein R20is independently selected from C1-3 alkyl, -C0-1 alkyl-(C3-4 carbocycle) optionally substituted with one or more halogen, 4- to 8-membered heterocycle, and -(2- to 3-membered heteroalkyl)-( C3-4 carbocycle) optionally su
[0474] In some embodiments, RB2is selected from
[0475]
[0476]
[0477]
[0099] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(C1-3 alkylene)-(C3-5 carbocycle)-(C1-3 alkylene)-(4- to 10-membered heterocycle) optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, C1-6 alkyl,Attorney Docket No. 56690-815601
[0478] C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein Ci-e alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -
[0479]
[0480] Attorney Docket No. 56690-815601
[0481]
[0482] some embodiments, RB2is -O(C1-3 alkylene)-(C3-5 carbocycle)-(C1-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, and C1-6 haloalkyl, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH; RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-4 carbocycle, and 3-to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In
[0483]
[0484] Attorney Docket No. 56690-815601
[0485]
[0486]
[0100] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with one, two, or three substituents independently selected from halogen, -CN, C1-3 alkyl, -C0-1 alkyl-(C3-6 carbocycle), and 4- to 6-membered heterocycle; wherein C1-3 alkyl, C0-1 alkyl-(C3-6 carbocycle), and 4- to 6-membered heterocycle, are optionally substituted with one or more substituents independently selected from
[0487]
[0488] Attorney Docket No. 56690-815601
[0489]
[0490]
[0101] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-
[0491]
[0492] embodiments, RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl. In some embodiments, RB2is selected from
[0493]
[0494] Attorney Docket No. 56690-815601
[0495]
[0496]
[0102] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(C1-3 alkylene)(5-membered saturated heterocycle comprising one ring nitrogen atom), wherein (5-membered saturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-6 carbocycle), 4- to 6-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2; wherein RB21is independently selected at each occurrence from hydrogen and halogen; RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C3-8 carbocycle, and 4- to 6-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In embodiments RB2is -O(C1-3 alkylene)(5-membered saturated heterocycle comprising one ring nitrogen atom), wherein (5-membered saturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-6 carbocycle), 4- to 6-membered heterocycle, -O(C1-3 alkyl), -O(C3-6 carbocycle), -O(4- to 5-membered heterocycle), -N(CH3)2, =C(RB21)2; wherein RB21is independently selected at each occurrence from hydrogen and halogen. In embodiments RB2is selected from
[0497]
[0498]
[0499] ,,,,,,,,,,Attorney Docket No. 56690-815601
[0500]
[0501] r20; wherein R20is independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2. In some embodiments, RB2
[0502]
[0503]
[0504]
[0103] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(C1-3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms), optionally substituted with one unsubstituted C1-3 alkyl. In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -OCH(CH3)-(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms), optionally substituted with one unsubstituted C1-3
[0505]
[0506]
[0104] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(C1-3 alkylene)-(C3-5 carbocycle)-(C1-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at eachAttorney Docket No. 56690-815601
[0507]
[0508]
[0105] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci-3 alkylene)-(6-membered heterocycle), wherein the 6-membered heterocycle comprises one or two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(6-membered heterocycle) is optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, -Co-i alkyl-(C3-4 carbocycle), 3- to 5-membered heterocycle, -ORB22, -N(RB22)(RB23), and -C(O)RB22; wherein Ci-6 alkyl and 3- to 5-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, Ci-6 alkyl, -ORB22, and -N(RB22)(RB23); RB22is independently selected at each occurrence from hydrogen, Ci-6 alkyl, Ci-6 haloalkyl, and C3-4 carbocycle; and RB23is independently selected at each occurrence from hydrogen and Ci-e
[0509]
[0510] Attorney Docket No. 56690-815601
[0511]
[0512]
[0106] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is (5-membered saturated heterocycle comprising one ring nitrogen atom), wherein (5-membered saturated heterocycle comprising one ring nitrogen atom) is substituted with one or more substituents independently selected from C1-3 alkyl, 5- to 6-membered heterocycle, and -N(RB22)(RB23), wherein C1-3 alkyl is optionally substituted with -N(RB22)(RB23) and 5- to 6-membered heterocycle is optionally substituted with C1-3 alkyl; wherein RB22is independently selected at each occurrence from hydrogen and C1-6 alkyl; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In embodiments RB2is (5 -membered saturated heterocycle comprising one ring nitrogen atom), wherein (5-membered saturated heterocycle comprising one ring nitrogen atom) is substituted with one or more substituents independently selected from C1-3 alkyl, 5- to 6-membered heterocycle, and -N(CH3)2, =C(RB21)2; wherein C1-3 alkyl is optionally substituted with -N(CH3)2 and 5-to 6-membered heterocycle is optionally substituted with C1-3 alkyl. In embodiments RB2is selected from
[0513]
[0514]
[0107] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(C1-3alkylene)(C3-6non-aromatic carbocycle), wherein (C3-6non-aromatic carbocycle) is substituted with one or more substituents independently selected from C1-3 alkyl, -ORB22, and -N(RB22)(RB23); wherein RB22is independently selected at each occurrence from hydrogen and C1-6 alkyl; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In embodiments RB2is -O(C1-3alkylene)(C3-6non-aromatic carbocycle), wherein (C3-6non-aromatic carbocycle) is substituted with one or more substituents independently selected from C1-3 alkyl, -O(CH3), -N(CH3)2, and -N(CH3)(CH2CH3). In some embodiments, RB2is
[0515]
[0516] Attorney Docket No. 56690-815601
[0517]
[0108] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(C4-e non-aromatic carbocycle), wherein (C4-6 non-aromatic carbocycle) is substituted with one or more substituents independently selected from C1-3 alkyl and -N(RB22)(RB23); wherein C1-3 alkyl is optionally substituted with -N(RB22)(RB23); wherein RB22is independently selected at each occurrence from hydrogen and C1-6 alkyl; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In embodiments RB2is -O(C4-6non-aromatic carbocycle), wherein (C4-6 non-aromatic carbocycle) is substituted with one or more substituents independently selected from C1-3 alkyl and -N(CH3)2; wherein C1-3 alkyl is optionally substituted with -
[0518]
[0519] N(CH3)2. In some embodiments, RB2is selected from
[0520] N. and I.
[0521]
[0109] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci.3alkylene)(5- to 6-membered saturated heterocycle comprising one ring oxygen atom), wherein (5- to 6-membered saturated heterocycle comprising one ring oxygen atom) is substituted with one or more substituents independently selected from C1-3 alkyl and -N(RB22)(RB23); wherein RB22is independently selected at each occurrence from hydrogen and C1-6 alkyl; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In embodiments RB2is -O(Ci.3alkylene)(5- to 6-membered saturated heterocycle comprising one ring oxygen atom), wherein (5- to 6-membered saturated heterocycle comprising one ring oxygen atom) is substituted
[0522] with one or more -N(CH3)2. In embodiments RB2is selected from
[0523]
[0524] [HO] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci.3alkylene)(bicyclic fused 6- to 10-membered heterocycle), wherein (bicyclic fused 6-to 10-membered heterocycle) is substituted with one or more substituents independently selected from C1-3 alkyl. In
[0525]
[0526] [Hl] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci.3alkylene)(bicyclic fused Ce-s saturated carbocycle), wherein (bicyclic fused Ce-s saturated carbocycle) is substituted with one or more substituents independently selected from -N(RB22)(RB23); wherein RB22is independently selected at each occurrence from hydrogen and C1-6 alkyl; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl. In embodiments RB2is -O(Ci.3alkylene)(bicyclic fusedAttorney Docket No. 56690-815601
[0527] Ce-s saturated carbocycle), wherein (bicyclic fused Ce-s saturated carbocycle) is substituted with one or more -
[0528] N(CH3)2. In some embodiments, RB2is selected from
[0529]
[0530]
[0112] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci-3 alkylene)(4- to 7-membered saturated heterocycle comprising one or two ring nitrogen atoms), wherein (4- to 7-membered saturated heterocycle comprising one or two ring nitrogen atoms) is
[0531] substituted with one or more C1-3alkyl. In embodiments RB2is selected from
[0532]
[0533]
[0113] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB2is -O(Ci-3 alkylene)(bicyclic spirocyclic 6- to 7-membered saturated heterocycle comprising one ring nitrogen atom), wherein (bicyclic spirocyclic 6- to 7-membered saturated heterocycle comprising one ring nitrogen atom) is substituted with one or more substituents independently selected from halogen and C1-3 alkyl. In embodiments RB2is -O(Ci-3 alkylene)( bicyclic spirocyclic 6- to 7-membered saturated heterocycle comprising one ring nitrogen atom), wherein (bicyclic spirocyclic 6- to 7-membered saturated heterocycle comprising one ring nitrogen atom) is substituted with one or more substituents independently selected from fluoro and C1-3 alkyl. In
[0534] embodiments RB2is selected from
[0535]
[0536]
[0114] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB6is selected from hydrogen, halogen, and C1-3 haloalky 1. In embodiments, RB6is halogen. In embodiments, RB6is -CF3.
[0537]
[0115] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB7is selected from Ce-i2 aryl and 5- to 12-membered heteroaryl, each of which is optionally substituted with one or more RB2° In embodiments, RB7is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more RB2° In embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, C2-3 alkynyl, -ORB22, -N(RB22)(RB23), and C3-6 cycloalkyl. In embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, -CH3, -CH2CH3, -CH=CH2, -CF3, -OCH3, -OH, -NH2, and -cyclopropyl.
[0538]
[0116] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt or solvate thereof, RB8is independently selected from hydrogen and halogen. In embodiments, RB8is halogen. In embodiments, RB8is F.
[0539]
[0117] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), or a salt orAttorney Docket No. 56690-815601
[0540] solvate thereof, RB6is halogen; RB7is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more RB20; and RB8is halogen.
[0541]
[0118] In some embodiments, the present disclosure provides a compound of Formula (AO-1), (AO-2), or (AO-3):
[0542]
[0543] or a pharmaceutically acceptable salt or solvate thereof, wherein all variables above are as described for Formula (AO), or any embodiment thereof.
[0544]
[0119] In some embodiments, the present disclosure provides a compound of Formula (A-l), (A-2), or (A-3):
[0545]
[0546] or a pharmaceutically acceptable salt or solvate thereof, wherein all variables above are as described for Formula (A), or any embodiment thereof.
[0547]
[0120] In some embodiments, the present disclosure provides a compound of Formula (aO-1), (aO-2), or (a0-3):
[0548]
[0549] or a pharmaceutically acceptable salt or solvate thereof, wherein all variables above are as described for Formula (aO), or any embodiment thereof.
[0550]
[0121] In some embodiments, the present disclosure provides a compound of Formula (a-l), (a-2), or (a-3):
[0551]
[0552] or a pharmaceutically acceptable salt or solvate thereof, wherein all variables above are as described for Formula (a), or any embodiment thereof.
[0553]
[0122] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3),Attorney Docket No. 56690-815601
[0554] (A), (A-l), (A-2), (A-3), (a), (a- 1), (a-2), or (a-3), the compound has the formula
[0555]
[0556]
[0557] 1), (A-2), (A-3), (a), (a-l), (a-2), (a-3), or any embodiment thereof. In some embodiments, the compound has formula (A-7). In some embodiments, the compound has formula (a-7). In some embodiments, the compound has formula (A-8). In some embodiments, the compound has formula (a-8).
[0558]
[0123] In some embodiments, for a compound of Formula (AO), (AO-1), (aO), (aO-1), (A), (A-l), (A-4), (a), (a-l), or (a-4), Z6is selected from C(RB6), C(RB6)2, N, O, and N(RB6b). In some embodiments, Z6is selected from C(RB6) and C(RB6)2. In some embodiments, Z6is selected from N and N(RB6b). In some embodiments, Z6is selected from C(RB6) and N. In some embodiments, Z6is selected from C(RB6)2and N(RB6b). In some embodiments, Z6is C(RB6). In some embodiments, Z6is C(RB6)2. In some embodiments, Z6is N. In some embodiments, Z6is N(RB6b).
[0559]
[0124] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (a), (a-l), (a-2), or (a-3), Z7is selected from C(RB7) and N(RB7b). In some embodiments, Z7is C(RB7). In some embodiments, Z7is N(RB7b).
[0560]
[0125] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (a), (a-l), (a-2), or (a-3), Z8is selected from C(RB8), N, and C(RB8)2. In some embodiments, Z8is selected from C(RB8) and C(RB8)2. In some embodiments, Z8is C(RB8). In some embodiments, Z8is C(RB8)2. In some embodiments, Z8is N.
[0561]
[0126] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (aO), (aO-1), (aO-2), (A), (A-l), (A-2), (a), (a-l), or (a-2), RB6is selected from hydrogen, halogen, -CN, Ci-6 alkyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -ORB12, and -N(RB12)(RB13), wherein Ci-6 alkyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°. In some embodiments, RB6is selected from hydrogen, halogen, and Ci -3 alkyl. In some embodiments, RB6is selected from hydrogen and halogen. In some embodiments, RB6is hydrogen. In some embodiments, RB6is halogen, such as chlorine. In some embodiments, RB6is -Cl. In some embodiments, RB6is -F. In some embodiments, RB6is fluorine. In some embodiments, RB6is Ci-6 alkyl optionally substituted with one or more independently selected halogen. In some embodiments, RB6is -CF3. In some embodiments, Z6is C(RB6)2and each RB6is hydrogen.
[0562]
[0127] In some embodiments (e.g., a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), RB7is selected from C3-12carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more RB2°; and RB7bisAttorney Docket No. 56690-815601
[0563] selected from C3-12 carbocycle, -C(O)-(C3-i2 carbocycle), 6- to 12-membered heterocycle, and -C(O)-(3- to 12-membered heterocycle), each of which is optionally substituted with one or more RB2°
[0564]
[0128] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), RB7is selected from Ce-i2 aryl and 5-to 12-membered heteroaryl, each of which is optionally substituted with one or more RB20. In some embodiments, RB7is selected from Ce aryl and 6-membered heteroaryl, each of which is substituted with one, two, three, four, or five RB20. In some embodiments, RB7is phenyl substituted with one, two, three, or four substituents independently selected from halogen, -CN, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, C2-3 alkynyl, -ORB22, -N(RB22)(RB23), and C3-6 cycloalkyl. In some embodiments, RB7is phenyl substituted with one, two, three, or four substituents independently selected from -F, -Cl, -CN, -CH3, -CH2CH3, -CH=CH2, -CF3, -C≡CH, -OH, -NH2, and -cyclopropyl. In some embodiments, RB7is optionally substituted with one or more RB20, such as one, two, three, four, five, six, or seven RB2°
[0565]
[0129] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-
[0566]
[0567]
[0568] , wherein:
[0569] Q1, Q3, and Q5are independently selected from N and C(Rlq);
[0570] Q4and Q6are independently selected from O, S, C(Rlq)2, and N(Rlr);
[0571] Y4, Y5, Y6, Y9, and Y10are independently selected from C(Rlq) and N;
[0572] Y7and Y8are independently selected from C(Rlq), C(Rlq)2, N, and N(Rlr);
[0573] Y13is selected from a bond, C(Rlq), N, C(O), C(Rlq)2, C(O)C(Rlq)2, C(Rlq)2C(Rlq)2, C(Rlq)2N(Rlr), and N(Rlr);
[0574] Y14, Y15, Y17, and Y18are independently selected from C(O), C(Rlq), N, C(Rlq)2, and N(Rlr);
[0575] Y16is selected from C, N, and C(Rlq);
[0576] each Rlqis independently selected from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -Attorney Docket No. 56690-815601
[0577] OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein Ci-6 alkyl,
[0578]
[0579] membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°; or two Rlqbonded to the same carbon are joined to form 3- to 10-membered heterocycle or C3-10 carbocycle, wherein 3- to 10-membered heterocycle and C3-10 carbocycle are optionally substituted with one, two, or three RB20; or two Rlqbonded to adjacent atoms are joined to form 3- to 10-membered heterocycle or C3-10 carbocycle, wherein 3- to 10-membered heterocycle and C3-10 carbocycle are optionally substituted with one, two, or three RB20; or one Rlqand one Rlrare joined to form 3- to 10-membered heterocycle or C3-10 carbocycle, wherein 3- to 10-membered heterocycle and C3-10 carbocycle are optionally substituted with one, two, or three RB20;
[0580] each Rlris independently selected from hydrogen, C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, 3- to 10-membered heterocycle, and C3-10 carbocycle, wherein C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, 3- to 10-membered heterocycle, and C3-10 carbocycle are optionally substituted with one, two, or three RB20; and
[0581] indicates a single or double bond such that all valences are satisfied.
[0582]
[0583] Attorney Docket No. 56690-815601
[0584]
[0585] Attorney Docket No. 56690-815601
[0586]
[0587] embodiments,
[0588]
[0589] some embodiments,
[0590]
[0591] some embodiments, RB7is
[0592]
[0593] , some embodiments,
[0594]
[0595]
[0132] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, -ORB22, -SRB22, and -N(RB22)(RB23), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl are optionally substituted with one, two, or three substituents independently selected from halogen, Ci-e alkyl, C1-6 haloalkyl, and -ORB22. In some embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, C2-3 alkynyl, -ORB22, -N(RB22)(RB23), and C3-6 cycloalkyl. In some embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, -CH3, -CH2CH3, -CH=CH2, -CF3, -C≡CH, -OH, -NH2, and -cyclopropyl. In some embodiments, RB7is substituted with one, two, three, or four substituents independentlyAttorney Docket No. 56690-815601
[0596] selected from -F, -Cl, -CN, -CH3, -CH2CH3, -CH=CH2, -CF3, -C≡CH, -OH, -NH2, and -cyclopropyl. In some embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, Ci-3alkyl, C2.3alkenyl, C2.3alkynyl, -ORB22, and -N(RB22)(RB23). In some embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, -CH3, -C≡CH, -OH, and -NH2. In some embodiments, RB7is substituted with -F, -CN, and -NH2. In some embodiments, RB7is substituted with -F, -C≡CH, and -OH. In some embodiments, RB7is substituted with -CF3, -CH3, and -NH2. In some embodiments, RB7is substituted with -CF3and -NH2. In some embodiments, RB7is substituted with -CF3, -CH3, -F, and -NH2. In some embodiments, RB7is substituted with -CF3, -F, and -NH2. In some embodiments, RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, -CH3, -CH2CH3, -CH=CH2, -CF3, -C≡CH, -OH, -NH2, and -cyclopropyl.
[0597]
[0133] In some embodiments, for a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), RB8is selected from hydrogen, halogen, -CN, Ci-6 alkyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -ORB12, and -N(RB12)(RB13), wherein Ci-6 alkyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3.i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2° In some embodiments, RB8is selected from hydrogen, halogen, and Ci-3alkyl. In some embodiments, RB8is selected from hydrogen and halogen. In some embodiments, RB8is hydrogen. In some embodiments, RB8is halogen, such as chlorine. In some embodiments, RB8is -Cl. In some embodiments, RB8is -F. In some embodiments, RB8is -CF3. In some embodiments, RB8is Ci-6 alkyl optionally substituted with one or more halogen. In some embodiments, RB8is fluorine. In some embodiments, Z8is C(RB8)2and each RB8is hydrogen.
[0598]
[0134] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8), Q2is 4- to 10-membered heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 4-membered heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 5-membered heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 6-membered heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 7-membered heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 8-membered heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 9-membered heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 10-membered heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, a heterocycle recited in this paragraph is fully saturated or partially unsaturated. In some embodiments, a heterocycle recited in this paragraph is fully saturated. In some embodiments, a heterocycle recited in this paragraph is partially unsaturated. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring nitrogen atom. In some embodiments, a heterocycle recited in this paragraph comprises at least two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises exactly two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring oxygen atom. In some embodiments, a heterocycle recited in this paragraph comprises one ring nitrogen atom and one ring oxygen atom.
[0599]
[0135] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8), Q2is 6- to 9-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 6-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 7-memberedAttorney Docket No. 56690-815601
[0600] bridged bicyclic heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 8-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 9-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is 6- to 9-membered bridged bicyclic heterocycloalkyl, which (i) comprises only one ring heteroatom and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 6-membered bridged bicyclic heterocycloalkyl, which (i) comprises only one ring heteroatom and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 7-membered bridged bicyclic heterocycloalkyl, which (i) comprises only one ring heteroatom and (ii) is optionally substituted with one or more RB2° In some embodiments, Q2is a 8-membered bridged bicyclic heterocycloalkyl, which (i) comprises only one ring heteroatom and (ii) is optionally substituted with one or more RB2° In some embodiments, Q2is a 9-membered bridged bicyclic heterocycloalkyl, which (i) comprises only one ring heteroatom and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is 6- to 9-membered bridged bicyclic heterocycloalkyl, which (i) comprises at least two ring heteroatoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 6-membered bridged bicyclic heterocycloalkyl, which (i) comprises at least two ring heteroatoms and (ii) is optionally substituted with one or more RB2° In some embodiments, Q2is a 7-membered bridged bicyclic heterocycloalkyl, which (i) comprises at least two ring heteroatoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 8-membered bridged bicyclic heterocycloalkyl, which (i) comprises at least two ring heteroatoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 9-membered bridged bicyclic heterocycloalkyl, which (i) comprises at least two ring heteroatoms and (ii) is optionally substituted with one or more RB20. In some embodiments, a heterocycle recited in this paragraph is fully saturated or partially unsaturated. In some embodiments, a heterocycle recited in this paragraph is fully saturated. In some embodiments, a heterocycle recited in this paragraph is partially unsaturated. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring nitrogen atom. In some embodiments, a heterocycle recited in this paragraph comprises at least two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises exactly two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring oxygen atom. In some embodiments, a heterocycle recited in this paragraph comprises one ring nitrogen atom and one ring oxygen atom. In some embodiments, Q2is 6- to 9-membered bridged bicyclic heterocycloalkyl, which (i) comprises two ring nitrogen atoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 6-membered bridged bicyclic heterocycloalkyl, which (i) comprises two ring nitrogen atoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 7-membered bridged bicyclic heterocycloalkyl, which (i) comprises two ring nitrogen atoms and (ii) is optionally substituted with one or more RB2° In some embodiments, Q2is a 8-membered bridged bicyclic heterocycloalkyl, which (i) comprises two ring nitrogen atoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is a 9-membered bridged bicyclic heterocycloalkyl, which (i) comprises two ring nitrogen atoms and (ii) is optionally substituted with one or more RB20. In some embodiments, Q2is 6- to 10-membered fused bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 6-membered fused bicyclic heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 7-membered fused bicyclic heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 8-membered fused bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 9-membered fused bicyclic heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 10-membered fused bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, aAttorney Docket No. 56690-815601
[0601] heterocycle recited in this paragraph is fully saturated or partially unsaturated. In some embodiments, a heterocycle recited in this paragraph is fully saturated. In some embodiments, a heterocycle recited in this paragraph is partially unsaturated. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring nitrogen atom. In some embodiments, a heterocycle recited in this paragraph comprises at least two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises exactly two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring oxygen atom. In some embodiments, a heterocycle recited in this paragraph comprises one ring nitrogen atom and one ring oxygen atom. In some embodiments, Q2is 6- to 12-membered spirocyclic bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 6-membered spirocyclic bicyclic heterocycloalkyl optionally substituted with one or more RB2° In some embodiments, Q2is a 7-membered spirocyclic bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 8-membered spirocyclic bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 9-membered spirocyclic bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, Q2is a 10-membered spirocyclic bicyclic heterocycloalkyl optionally substituted with one or more RB20. In some embodiments, a heterocycle recited in this paragraph is fully saturated or partially unsaturated. In some embodiments, a heterocycle recited in this paragraph is fully saturated. In some embodiments, a heterocycle recited in this paragraph is partially unsaturated. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring nitrogen atom. In some embodiments, a heterocycle recited in this paragraph comprises at least two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises exactly two ring nitrogen atoms. In some embodiments, a heterocycle recited in this paragraph comprises at least one ring oxygen atom. In some embodiments, a heterocycle recited in this paragraph comprises one ring nitrogen atom and one ring oxygen atom.
[0602]
[0603]
[0604] Attorney Docket No. 56690-815601
[0605] substituted with one or more RB20. In some embodiments, Q2is selected from
[0606]
[0607] ,
[0608]
[0609]
[0610] ,
[0611]
[0612] of which is optionally substituted with one or more RB20.
[0613]
[0137] In some embodiments,
[0614]
[0615] , which is optionally substituted with one or more RB2° In some, which is optionally substituted with one or more RB20. In
[0616]
[0617] i, which is optionally substituted with one or more RB20. In some embodiments,
[0618]
[0619] optionally substituted with one or more RB20. In some embodiments, Q2is
[0620]
[0621] , which is optionally substituted with one or more RB20. In some embodiments, Q2is
[0622]
[0623] , which is optionally substituted with one or more RB20.
[0624]
[0625] In some embodiments, Q2is I, which is optionally substituted with one or more RB20. In some embodiments,
[0626]
[0627] Q2is, which is optionally substituted with one or more RB20. In some embodiments, Q2is, whichAttorney Docket No. 56690-815601
[0628] is optionally substituted with one or more RB20. In some embod, which is optionally
[0629] substituted with one or more RB2° In some embodiments, Q2is
[0630]
[0631] , tionally substituted with one or
[0632]
[0633] more RB20. In some embodiments, Q2is I, which is optionally substituted with one or more RB20. In some
[0634] embodiments,
[0635]
[0636] , which is optionally substituted with one or more RB20. In some embodiments, Q2is
[0637]
[0638] !, which is optionally substituted with one or more RB2° In some embodiments, Q2is!, which is
[0639]
[0640] optionally substituted with one or more RB20. In some embodiments, Q2is I, which is optionally substituted
[0641]
[0642] with one or more RB20. In some embodiments, Q2is!, which is optionally substituted with one or more RB20.
[0643]
[0644] In some embodiments, Q2is!, which is optionally substituted with one or more RB20. In some embodiments,
[0645]
[0646] is optionally substituted with one or more RB2° In some embodiments, Q2is, which is optionally
[0647]
[0648] substituted with one or more RB2° In some embodiments, Q2is, which is optionally substituted with one or
[0649]
[0650] more RB20. In some embodiments, Q2is!, which is optionally substituted with one or more RB20.
[0651]
[0138] It will be understood that when Q2is substituted
[0652]
[0653] RB20), any hydrogen on one or more carbon and / or nitrogen atoms of the embodiments above, (e.g.,Attorney Docket No. 56690-815601
[0654]
[0655] replaced with the substituent.
[0656]
[0139] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), RB20is independently selected at each occurrence from halogen, oxo, -CN, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently halogen. In embodiments, RB20is independently -F. In embodiments, RB20is independently -Cl. In embodiments, RB2° jsindependently -Br. In embodiments, RB20is independently -I. In embodiments, RB20is independently oxo. In embodiments, RB20is independently -CN. In embodiments, RB20is independently C1-6 alkyl. In embodiments, RB20is independently C2-6 alkenyl. In embodiments, RB20is independently C2-6 alkynyl. In embodiments, RB20is independently 2- to 6-membered heteroalkyl. In embodiments, RB20is independently 3- to 6-membered heteroalkenyl. In embodiments, RB20is independently 3- to 6-membered heteroalkynyl. In embodiments, RB20is independently -Co-6 alkyl-(C3-i2 carbocycle). In embodiments, RB20is independently -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle). In embodiments, RB20is independently -Co-6 alkyl-(3- to 12-membered heterocycle). In embodiments, RB20is independently -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle). In embodiments, RB20is independently -ORB22. In embodiments, RB20is independently -SRB22. In embodiments, RB20is independently -N(RB22)(RB23). In embodiments, RB20is independently =NRB22. In embodiments, RB20isAttorney Docket No. 56690-815601
[0657] independently =C(RB21)2. In embodiments, RB20is independently -C(O)ORB22. In embodiments, RB20is independently -OC(O)N(RB22)(RB23). In embodiments, RB20is independently -N(RB22)C(O)N(RB22)(RB23). In embodiments, RB20is independently -N(RB22)C(O)ORB22. In embodiments, RB20is independently -N(RB22)S(O)2RB22. In embodiments, RB20is independently -C(O)RB22. In embodiments, RB20is independently -S(O)RB22. In embodiments, RB20is independently -OC(O)RB22. In embodiments, RB20is independently -C(O)N(RB22)(RB23). In embodiments, RB20is independently -C(O)C(O)N(RB22)(RB23). In embodiments, RB20is independently -N(RB22)C(O)RB22. In embodiments, RB20is independently -S(O)2RB22. In embodiments, RB20is independently -S(O)(NRB22)RB22. In embodiments, RB20is independently -S(O)2N(RB22)(RB23)-. In embodiments, RB20is independently -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, two RB20attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle. In embodiments, two RB20attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle, wherein C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C2-6 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C2-6 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently 2- to 6-membered heteroalkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently 3- to 6-membered heteroalkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -Attorney Docket No. 56690-815601
[0658] N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently 3- to 6-membered heteroalkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently -Co-6 alkyl-(C3-i2carbocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently -(2- to 6-membered heteroalkyl)-(C3-12carbocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently -Co-6 alkyl-(3- to 12-membered heterocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently Ci alkyl. In embodiments, RB20is independently C2alkyl. In embodiments, RB20is independently C3 alkyl. In embodiments, RB20is independently C4 alkyl. In embodiments, RB20is independently C5 alkyl. In embodiments, RB20is independently Ce alkyl. In embodiments, RB20is independently Ci alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C2alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -Attorney Docket No. 56690-815601
[0659] OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C3 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C1-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C4 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C5 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently G, alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C2alkenyl. In embodiments, RB20is independently C3 alkenyl. In embodiments, RB20is independently C4 alkenyl. In embodiments, RB20is independently C5 alkenyl. In embodiments, RB20is independently Ce alkenyl. In embodiments, RB20is independently C2alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C3 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C4 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C5 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6Attorney Docket No. 56690-815601
[0660] haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently Ce alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C2alkynyl. In embodiments, RB20is independently C3 alkynyl. In embodiments, RB2° jsindependently C4 alkynyl. In embodiments, RB20is independently C5 alkynyl. In embodiments, RB20is independently Ce alkynyl. In embodiments, RB20is independently C2alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-e haloalkyl, Ci-e hydroxyalkyl, Ci-e alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C3 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C4 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently C5 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently Ce alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-e haloalkyl, Ci-e hydroxyalkyl, Ci-e alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB20is independently -OH. In embodiments, RB20is independently -SH. In embodiments, RB20is independently -NH2. In embodiments, RB20is independently =NH. In embodiments, RB20is independently =CH2. In embodiments, RB20is independently -C(O)OH. In embodiments, RB20is independently -C(O)CH3. In embodiments, RB20is independently -S(O)RB22. InAttorney Docket No. 56690-815601
[0661] embodiments, RB20is independently -OC(O)CH3. In embodiments, RB20is independently -C(O)NH2. In embodiments, RB20is independently -N(RB22)C(O)CH3. In embodiments, RB20is independently -OCH3. In embodiments, RB20is independently -SCH3. In embodiments, RB20is independently -N(CH3)2.
[0662]
[0140] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), RB9is independently hydrogen. In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8), RB9is independently selected at each occurrence from halogen, oxo, -CN, Ci-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3. i2carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein Ci-6alkyl, C2.6alkenyl, C2.6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i2carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-i2carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently halogen. In embodiments, RB9is independently -F. In embodiments, RB9is independently -Cl. In embodiments, RB9is independently -Br. In embodiments, RB9is independently -I. In embodiments, RB9is independently oxo. In embodiments, RB9is independently -CN. In embodiments, RB9is independently Ci-6 alkyl. In embodiments, RB9is independently C2.e alkenyl. In embodiments, RB9is independently C2.e alkynyl. In embodiments, RB9is independently 2- to 6-membered heteroalkyl. In embodiments, RB9is independently 3- to 6-membered heteroalkenyl. In embodiments, RB9is independently 3- to 6-membered heteroalkynyl. In embodiments, RB9is independently -Co-6 alkyl-(C3-i2carbocycle). In embodiments, RB9is independently -(2- to 6-membered heteroalkyl)-(C3.i2carbocycle). In embodiments, RB9is independently -Co-6 alkyl-(3- to 12-membered heterocycle). In embodiments, RB9is independently -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle). In embodiments, RB9is independently -ORB22. In embodiments, RB9is independently -SRB22. In embodiments, RB9is independently -N(RB22)(RB23). In embodiments, RB9is independently =NRB22. In embodiments, RB9is independently =C(RB21)2. In embodiments, RB9is independently -C(O)ORB22. In embodiments, RB9is independently -OC(O)N(RB22)(RB23). In embodiments, RB9is independently -N(RB22)C(O)N(RB22)(RB23). In embodiments, RB9is independently -N(RB22)C(O)ORB22. In embodiments, RB9is independently -N(RB22)S(O)2RB22. In embodiments, RB9is independently -C(O)RB22. In embodiments, RB9is independently -S(O)RB22. In embodiments, RB9is independently -OC(O)RB22. In embodiments, RB9is independently -C(O)N(RB22)(RB23). In embodiments, RB9is independently -C(O)C(O)N(RB22)(RB23). In embodiments, RB9is independently -N(RB22)C(O)RB22. In embodiments, RB9is independently -S(O)2RB22. In embodiments, RB9is independently -S(O)(NRB22)RB22. In embodiments, RB9is independently -S(O)2N(RB22)(RB23)-. In embodiments, RB9is independently -S(=O)(=NRB22)N(RB22)(RB23). InAttorney Docket No. 56690-815601
[0663] embodiments, two RB9attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle. In embodiments, two RB9attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle, wherein C3-12 carbocycle and 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, Ci-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C2-6 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C2-6 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently 2- to 6-membered heteroalkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently 3- to 6-membered heteroalkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently 3- to 6-membered heteroalkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently -Co-6 alkyl-(C3-i2 carbocycle) optionally substituted with one or moreAttorney Docket No. 56690-815601
[0664] substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently -(2- to 6-membered heteroalkyl)-(C3-12carbocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently -Co-6 alkyl-(3- to 12-membered heterocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently Ci alkyl. In embodiments, RB9is independently C2alkyl. In embodiments, RB9is independently C3 alkyl. In embodiments, RB9is independently C4 alkyl. In embodiments, RB9is independently C5 alkyl. In embodiments, RB9is independently Ce alkyl. In embodiments, RB9is independently unsubstituted Ci alkyl. In embodiments, RB9is independently unsubstituted C2alkyl. In embodiments, RB9is independently unsubstituted C3 alkyl. In embodiments, RB9is independently unsubstituted C4 alkyl. In embodiments, RB9is independently unsubstituted C5 alkyl. In embodiments, RB9is independently unsubstituted Ce alkyl. In embodiments, RB9is independently Ci alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-e haloalkyl, Ci-e hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C2alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-e hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C3 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-e hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -Attorney Docket No. 56690-815601
[0665] OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C4 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, C1-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C5 alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C6alkyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C2alkenyl. In embodiments, RB9is independently C3 alkenyl. In embodiments, RB9is independently C4 alkenyl. In embodiments, RB9is independently C5 alkenyl. In embodiments, RB9is independently Ce alkenyl. In embodiments, RB9is independently unsubstituted C2alkenyl. In embodiments, RB9is independently unsubstituted C3 alkenyl. In embodiments, RB9is independently unsubstituted C4 alkenyl. In embodiments, RB9is independently unsubstituted C5 alkenyl. In embodiments, RB9is independently unsubstituted Ce alkenyl. In embodiments, RB9is independently C2alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-e hydroxyalkyl, Ci-e alkoxy, Ci-e haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C3 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C4 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C5 alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -Attorney Docket No. 56690-815601
[0666] OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C6alkenyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C2alkynyl. In embodiments, RB9is independently C3 alkynyl. In embodiments, RB9is independently C4 alkynyl. In embodiments, RB9is independently C5 alkynyl. In embodiments, RB9is independently Ce alkynyl. In embodiments, RB9is independently unsubstituted C2alkynyl. In embodiments, RB9is independently unsubstituted C3 alkynyl. In embodiments, RB9is independently unsubstituted C4 alkynyl. In embodiments, RB9is independently unsubstituted C5 alkynyl. In embodiments, RB9is independently unsubstituted Ce alkynyl. In embodiments, RB9is independently C2alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-6 haloalkyl, Ci-e hydroxyalkyl, Ci-e alkoxy, Ci-e haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C3 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C4 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, Ci-6 alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently C5 alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-6 alkyl, Ci-6 haloalkyl, C1.6 hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently Ce alkynyl optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, Ci-e alkyl, Ci-e haloalkyl, Ci-e hydroxyalkyl, Ci-6alkoxy, Ci-6haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23). In embodiments, RB9is independently -OH. In embodiments, RB9is independently -SH. In embodiments, RB9is independently -NH2. In embodiments, RB9is independently =NH. In embodiments, RB9is independently =CH2. In embodiments, RB9is independently -C(O)OH. In embodiments, RB9is independently -C(O)CH3. In embodiments, RB9is independently -S(O)RB22. InAttorney Docket No. 56690-815601
[0667] embodiments, RB9is independently -OC(O)CH3. In embodiments, RB9is independently -C(O)NH2. In embodiments, RB9is independently -N(RB22)C(O)CH3. In embodiments, RB9is independently -OCH3. In embodiments, RB9is independently -SCH3. In embodiments, RB9is independently -N(CH3)2.
[0668]
[0141] In some embodiments, only one RB9is non-hydrogen. In some embodiments, only two RB9are nonhydrogen. In some embodiments, only two RB9bonded to the same carbon atom are non-hydrogen. In some embodiments, only two RB9bonded to different carbon atoms are non-hydrogen. In some embodiments, only three RB9are non-hydrogen. In some embodiments, only four RB9are non-hydrogen. In some embodiments, only five RB9are non-hydrogen. In some embodiments, only six RB9are non-hydrogen. In some embodiments, all RB9are hydrogen.
[0669]
[0142] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), or (aO-
[0670]
[0671] some embodiments of a compound of Formula (AO), (AO-1), (AO-2),
[0672]
[0673]
[0674] some embodiments,
[0675]
[0676] Attorney Docket No. 56690-815601
[0677]
[0678]
[0679] some embodiments, only one RB9is non-hydrogen. In some embodiments, only two RB9are non-hydrogen. In some embodiments, only two RB9bonded to the same carbon atom are non-hydrogen. In some embodiments, only two RB9bonded to different carbon atoms are nonhydrogen. In some embodiments, only three RB9are non-hydrogen. In some embodiments, only four RB9are nonhydrogen. In some embodiments, only five RB9are non-hydrogen. In some embodiments, only six RB9are nonhydrogen. In some embodiments, all RB9are hydrogen.
[0680]
[0143] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), J1is a bond, J2is a bond, and J3is selected from Ci-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is C1-6 alkylene, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is ethylene, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is propylene, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is unsubstituted ethylene. In embodiments, J1is a bond, J2is a bond, and J3is unsubstituted propylene. In embodiments, J1is a bond, J2is a bond, and J3is -Co-6 alkyl-(C3-i2 carbocycle)-, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is C3-12 carbocycle, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is C3-6 carbocycle, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is C4-6 carbocycle, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is cyclobutylene, which is optionally substituted with one or more RB2°. In embodiments, J1is a bond, J2is a bond, and J3is cyclobutylene.
[0681]
[0144] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3),
[0682] (A), (A-l), (A-2), or (A-3)), or a salt or solvate thereof,
[0683]
[0684] selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, andAttorney Docket No. 56690-815601
[0685] 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, Ci-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3-to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O). In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3),
[0686] (A), (A-l), (A-2), or (A-3)), or a salt or solvate thereof,
[0687]
[0688] wherein: J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3-to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and
[0689] RBI6 (halo)oi
[0690] C(O). In embodiments,
[0691]
[0692]
[0693] wherein: J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from -CH(CH3)2and -C(CH3)3; RB16is selected from hydrogen, -CH3, and -CH2OH; RB17is selected from methylthiazole and methylpyrazole; ol is selected from 0 and 1; pl and ql are independently selected from 1 and 2; and X is selected from CH2and C(O). In embodiments,
[0694] O
[0695] O
[0696]
[0697] DG is ( a o)o1; wherein: J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from -CH(CH3)2and -C(CH3)3; RB16is selected from hydrogen, -CH3, and -CH2OH; RB17is selected from methylthiazole and methylpyrazole; ol is selected from 0 and 1; pl and ql are independently selected from 1 and 2; and X is selected from CH2and C(O).
[0698]
[0145] In embodiments of a compound described herein (e.g., compound of Formula (AO), (AO-1), (AO-2), (AO-3),Attorney Docket No. 56690-815601
[0699] (A), (A-l), (A-2), or (A-3)), or a salt or solvate thereof,
[0700]
[0701]
[0702]
[0703] , rm
[0704]
[0705] embodiments, DG comprises a monovalent form of
[0706]
[0707] ,, monovalent form
[0708]
[0709] embodiments, DG comprises a monovalent form ofAttorney Docket No. 56690-815601
[0710]
[0711] embodiments, DG comprises a monovalent form
[0712]
[0713] embodiments, DG comprises a monovalent form
[0714]
[0715] embodiments, DG comprises a
[0716]
[0717] ,
[0718] embodiments, DG comprises a monovalent form
[0719]
[0720] monovalent form of
[0721]
[0722] In embodiments, DG comprises a monovalent form of
[0723]
[0724] embodiments, DG comprises a monovalent form
[0725]
[0726] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof. In embodiments, DG comprises a monovalent form of
[0727]
[0728] embodiments, DG comprises a monovalent form
[0729]
[0730] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof. In embodiments, DG comprises a
[0731] monovalent form
[0732]
[0733] described for a compound of Formula (AO), (A), (aO), and / or (a), or anyAttorney Docket No. 56690-815601
[0734] embodiment thereof. In embodiments, DG comprises a monovalent form
[0735]
[0736] embodiments, DG
[0737] comprises a monovalent form
[0738]
[0739] described for a compound of Formula (AO), (A), (aO), and / or
[0740] (a), or any embodiment thereof. In embodiments, DG comprises a monovalent form
[0741]
[0742] embodiments, DG comprises a monovalent form
[0743]
[0744] embodiments, DG comprises a monovalent
[0745]
[0746] embodiments, DG comprises a monovalent form
[0747]
[0748] embodiments, DG
[0749] comprises a monovalent form
[0750]
[0751] embodiments, DG comprises a monovalent form
[0752]
[0753] RB22is as described for a compound of Formula (A) or (a), or any embodiment thereof. In embodiments, DG
[0754] comprises a monovalent form
[0755]
[0756] embodiments, DG comprises a monovalent form
[0757]
[0758] RB12is as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof. In embodiments,
[0759] DG comprises a monovalent form
[0760]
[0761] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / orAttorney Docket No. 56690-815601
[0762] (a), or any embodiment thereof. In embodiments, DG comprises a monovalent form
[0763]
[0764] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof. In embodiments, DG
[0765] comprises a monovalent form
[0766]
[0767] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or
[0768] (a), or any embodiment thereof. In embodiments, DG comprises a monovalent form
[0769]
[0770] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof. In embodiments, DG
[0771] comprises a monovalent form
[0772]
[0773] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or
[0774] (a), or any embodiment thereof. In embodiments, DG comprises a monovalent form
[0775]
[0776] described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof. In embodiments, DG
[0777] comprises a monovalent form
[0778]
[0779] described for a compound of Formula (AO), (A), (aO),
[0780] and / or (a), or any embodiment thereof. In embodiments, DG comprises a monovalent
[0781]
[0782] as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof; and RB22is as described for a compound of Formula (AO), (A), (aO), and / or (a), or any embodiment thereof.
[0783]
[0146] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (A), (A-l), (A-2), or (A-3),Attorney Docket No. 56690-815601
[0784] J1is a bond; J2is a bond; J3is unsubstituted ethylene; DG is selected from
[0785]
[0786]
[0787] membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, Ci-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O). In embodiments, J1is a bond; J2is a bond; J3is unsubstituted propylene; and DG, RB15, RB16, RB17, ol, pl, ql, and X are as described above in this paragraph. In embodiments, J1is a bond; J2is a bond; J3is cyclobutylene; and DG, RB15, RB16, RB17, ol, pl, ql, and X are as described above in this paragraph.
[0788]
[0147] In some embodiments of a compound of Formula (aO), (aO-1), (aO-2), (a0-3), (a), (a-1), (a-2), or (a-3), J1is a bond; J2is a bond; J3is unsubstituted ethylene; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(CI-3 alkyl), -N(CI-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle. In embodiments, J1is a bond; J2is a bond; J3is unsubstituted propylene; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(CI-3 alkyl), -N(CI-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle. In embodiments, J1is a bond; J2is a bond; J3is cyclobutylene; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(CI-3 alkyl), -N(CI-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle.
[0789]
[0148] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (a0-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-1), (a-2), (a-3), (a-7), or (a-8), J1is -C(O)-, J2is a bond, and J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)- (3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is C1-6 alkylene, which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is methylene, which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted methylene. In embodiments, J1is a -C(O)-, J2is a bond, and J3is ethylene (e.g., -CH(CH3)-), which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted ethylene (e.g., -CH(CH3)-). In embodiments, J1is a -C(O)-, J2is a bond, and J3is propylene (e.g., -CH(CH2CH3)-), which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted propylene (e.g., -CH(CH2CH3)-). In embodiments,Attorney Docket No. 56690-815601
[0790] J1is a -C(O)-, J2is a bond, and J3is butylene (e.g., -CH(CH(CH3)2)-), which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted butylene (e.g., -CH(CH(CH3)2)-). In embodiments, J1is a -C(O)-, J2is a bond, and J3is methylene, which is substituted with one or more unsubstituted C3-6carbocycle. In embodiments, J1is a -C(O)-, J2is a bond, and J3is methylene, which is substituted with one or more unsubstituted C3-4carbocycle. In embodiments, J1is a -C(O)-, J2is a bond, and J3is methylene, which is substituted with one or more unsubstituted cyclopropyl.. In embodiments, J1is a -C(O)-, J2is a bond, and J3is C2 alkylene (e.g., -CH(CH3)-), which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted C2 alkylene (e.g., -CH(CH3)-). In embodiments, J1is a -C(O)-, J2is a bond, and J3is C3alkylene (e.g., -CH(CH2CH3)-), which is optionally substituted with one or more RB2° In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted C3alkylene (e.g., -CH(CH2CH3)-). In embodiments, J1is a -C(O)-, J2is a bond, and J3is C4 alkylene (e.g., -CH(CH(CH3)2)-), which is optionally substituted with one or more RB20. In embodiments, J1is a -C(O)-, J2is a bond, and J3is unsubstituted C4 alkylene (e.g., -CH(CH(CH3)2)-). In embodiments, J1is a -C(O)-, J2is a bond, and J3is Ci alkylene, which is substituted with one or more unsubstituted C3-6 carbocycle. In embodiments, J1is a -C(O)-, J2is a bond, and J3is Ci alkylene, which is substituted with one or more unsubstituted C3.4 carbocycle. In embodiments, J1is a -C(O)-, J2is a bond, and J3is Ci alkylene, which is substituted with one or more unsubstituted cyclopropyl.
[0791]
[0149] In some embodiments of a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (A), (A-l), (A-2), or (A-3),
[0792] J1is a -C(O)-; J2is a bond; J3is unsubstituted methylene; DG is selected from
[0793]
[0794]
[0795] membered heteroalkenylene, and 3- to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20; RB15is selected from hydrogen, C1-6 alkyl, C3-8carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more RB20; RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20; RB17is selected from halogen, -CN, C1-3 alkyl, C3-6carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6carbocycle, and 4- to 6-membered heterocycle are optionally substituted with one or more RB20; ol is selected from 0, 1, and 2; pl and ql are independently selected from 1, 2, and 3; and X is selected from CH2and C(O). In embodiments, J1is a -C(O)-; J2is a bond; J3is unsubstituted ethylene (e.g., -CH(CH3)-; and DG, RB15, RB16, RB17, ol, pl, ql, and X are as described above in this paragraph. In embodiments, J1is a -C(O)-; J2is a bond; J3is unsubstituted propylene (e.g., -CH(CH2CH3)-; and DG, RB15, RB16, RB17, ol, pl, ql, and X are as described above in this paragraph. In embodiments, J1is a -C(O)-; J2is a bond; J3is unsubstituted butylene (e.g., -CH(CH(CH3)2)-; and DG, RB15, RB16, RB17, ol, pl, ql, and X are as described above in this paragraph. In embodiments, J1is a -C(O)-; J2is a bond; J3is methylene, which is substituted with one unsubstituted cyclopropyl; and DG, RB15, RB16, RB17, ol, pl, ql, and X are as described above in this paragraph.Attorney Docket No. 56690-815601
[0796]
[0150] In some embodiments of a compound of Formula (aO), (aO-1), (aO-2), (a0-3), (a), (a-1), (a-2), or (a-3), J1is a -C(O)-; J2is a bond; J3is unsubstituted methylene; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(C1-3 alkyl), -N(C1-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle. In embodiments, J1is a -C(O)-; J2is a bond; J3is unsubstituted ethylene (e.g., -CH(CH3)-; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(C1-3 alkyl), -N(C1-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle. In embodiments, J1is a -C(O)-; J2is a bond; J3is unsubstituted propylene (e.g., -CH(CH2CH3)-; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(CI-3 alkyl), -N(CI-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle. In embodiments, J1is a -C(O)-; J2is a bond; J3is unsubstituted butylene (e.g., -CH(CH(CH3)2)-; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(CI-3 alkyl), -N(CI-3 alkyl)2, C1-3 alkyl, and C3-4 carbocycle. In embodiments, J1is a -C(O)-; J2is a bond; J3is methylene, which is substituted with one unsubstituted cyclopropyl; LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4; and RB4is selected from -NH(CI-3 alkyl), -N(CI-3 alky 1)2, C1-3 alkyl, and C3-4 carbocycle.
[0797]
[0151] In some embodiments, for a compound described herein (e.g., compound of Formula (aO), (aO-1), (aO-2), (a0-3), (a), (a-1), (a-2), or (a-3)), LG is selected from -OS(O)2RB4, -OS(O)(NH)RB4, and -OS(O)(NCN)RB4. In some embodiments, LG is -OS(O)2RB4. In some embodiments, LG is -OS(O)(NRB4b)RB4.
[0798]
[0152] In some embodiments, LG is not mesylate or tosylate. In some embodiments, LG is not mesylate, triflate, or tosylate. In some embodiments, RB4is not -CH3or -methylphenyl. In some embodiments, RB4is not -CH3, CF3, or - me thy Ipheny 1. In some embodiments, RB4is not -CH3, unsubstituted phenyl, penta-substituted phenyl, or p-methylphenyl. In some embodiments, RB4is not -CH3, -CF3, unsubstituted phenyl, penta-substituted phenyl, or p-methylphenyl.
[0799]
[0153] In some embodiments, for a compound of Formula (aO), (aO-1), (aO-2), (a0-3), (a), (a-1), (a-2), or (a-3), RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), and -N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2-to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20. In some embodiments, RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), each of which is optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4is selected from C1-6 alkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one, two, three, or four RB20. In some embodiments, RB4is selected from C1-6 alkyl and -Co-6 alkyl-(C3-i2 carbocycle), each of which is optionally substituted with one, two, three, or four RB20. In some embodiments, RB4is selected from C1-6 alkyl and -Co-6 alkyl-(C3-i2 carbocycle), each of which is optionally substituted with one, two, three, or four RB20, wherein the C3-12 carbocycle is not phenyl. In some embodiments, RB4is selected from C1-6 alkyl and -Co-6 alkyl-(C3-i2 cycloalkyl), each of which is optionally substituted with one, two, three, or four RB20. In someAttorney Docket No. 56690-815601
[0800] embodiments, RB4is C1-6 alkyl optionally substituted with one, two, three, or four RB20. In some embodiments, RB4is C1-6 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec -butyl, tert-butyl, or pentyl. In some embodiments, RB4is selected from ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, and pentyl. In some embodiments, RB4is ethyl. In some embodiments, RB4is not methyl, phenyl or -methylphenyl. In some embodiments, RB4is 2- to 6-membered heteroalkyl optionally substituted with one, two, three, or four RB20. In some embodiments, RB4is -N(RB12)(RB13). In some embodiments, RB4is -NH(RB12). In some embodiments, RB4is -NH2. In some embodiments, RB4is -NH(C1-6 alkyl). In some embodiments, RB4is -NH(C1-3 alkyl). In some embodiments, RB4is -N(C1-6 alkyl)2. In some embodiments, RB4is -N(C1-3 alkyl)2. In some embodiments, RB4is -N(CH3)2. In some embodiments, RB4is -N(CH2CH3)2. In some embodiments, RB4is -NH(CH2CH3). In some embodiments, RB4is -NH(CH3).
[0801]
[0154] In some embodiments, for a compound of Formula (aO), (aO-1), (aO-2), (aO-3), (a), (a-1), (a-2), or (a-3), RB4bis selected from C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), each of which is optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4bis selected from C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4bis selected from C1-6 alkyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4bis selected from C1-6 alkyl and -Co-6 alkyl-(C3-i2carbocycle), each of which is optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4bis selected from C1-6 alkyl and -Co-6 alkyl-(C3-i2cycloalkyl), each of which is optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4bis C1-6 alkyl optionally substituted with one, two, three, or four RB20. In some embodiments, RB4bis C1-6 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, or pentyl. In some embodiments, RB4bis selected from ethyl, propyl, isopropyl, butyl, isobutyl, sec -butyl, tert-butyl, and pentyl. In some embodiments, RB4bis 2- to 6-membered heteroalkyl optionally substituted with one, two, three, or four RB2°. In some embodiments, RB4bis hydrogen. In some embodiments, RB4bis -CN. In some embodiments, RB4bis -C(O)ORB12. In some embodiments, RB4bis -C(O)RB12. In some embodiments, RB4bis -S(O)2RB12.
[0802] 3), LG
[0803]
[0804]
[0805] Attorney Docket No. 56690-815601
[0806] selected from
[0807]
[0808] In some embodiments, LG is
[0809]
[0810]
[0811]
[0156] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG is
[0812]
[0813] Attorney Docket No. 56690-815601
[0814]
[0815]
[0157] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG is
[0816]
[0817]
[0158] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG is
[0818]
[0819] Attorney Docket No. 56690-815601
[0820]
[0821] ,
[0822]
[0159] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG is
[0823]
[0824]
[0160] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG is
[0825]
[0826]
[0161] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG isAttorney Docket No. 56690-815601
[0827]
[0828]
[0162] In some embodiments of a compound of Formula (A-7) or (a-7); ^J’-k-^-DG is
[0829]
[0830]
[0163] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG isAttorney Docket No. 56690-815601
[0831]
[0832] Attorney Docket No. 56690-815601
[0833]
[0834] Attorney Docket No. 56690-815601
[0835]
[0836]
[0165] In some embodiments of a compound of Formula (A-7) or (a-7);:-J1-J2-J3-DG is
[0837]
[0838]
[0166] In some embodiments of a compound of Formula (A-7) or (a-7);:-F-J2-J3-DG is
[0839]
[0840]
[0841] ,.,,Attorney Docket No. 56690-815601
[0842]
[0843] embodiments, RB2is
[0844]
[0845] In embodiments,
[0846]
[0847]
[0848] ,,
[0849]
[0167] As used herein, the term “leaving group” refers to an atom or group that becomes detached from an atom in the residual or main part of the substrate in a specified reaction. The residual or main part of the substrate is also referred to herein as the “staying group”. Not wishing to be bound by any particular theory, the mechanism below is provided as an example to illustrate a non-limiting types of leaving group that may be found in compounds of the present disclosure. In the example below, nucleophilic attack on a compound of Formula (a) by an amine group of a degradation enhancer reactant results in the cleavage of a C-0 bond of the sulfonate ester of the compound of Formula (a), thereby forming the depicted compound of Formula (A) and the leaving group as two distinct molecules.
[0850]
[0851]
[0168] The chemical entities described herein can be synthesized according to one or more illustrative schemes herein and / or techniques known in the art. Materials used herein are either commercially available or prepared by synthetic methods generally known in the art. These schemes are not limited to the compounds listed in the examples or by any particular substituents, which are employed for illustrative purposes. Although various steps are described and depicted in Schemes 1-15, the steps in some cases may be performed in a different order than the order shown in Schemes 1-15. Various modifications to these synthetic reaction schemes may be made and will be suggested to one skilled in the art having referred to the present disclosure. Numberings or R groups in each scheme typically have the same meanings as those defined elsewhere herein unless otherwise indicated.
[0852]
[0169] Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from -10 °C to 200 °C. Further, except as otherwise specified, reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about -10 °C to about 110 °C over a period of about 1 to about 24 hours; reactions left to run overnightAttorney Docket No. 56690-815601
[0853] average a period of about 16 hours.
[0854]
[0170] In general, compounds of the disclosure may be prepared by the following reaction schemes:
[0855] Scheme 1
[0856]
[0857]
[0171] In some embodiments, a compound of Formula 11 may be prepared according to Scheme 1. For example, heteroaryl ether 1c can be formed from chloride la via a nucleophilic aromatic substitution reaction with alcohol lb (e.g., wherein PG is a suitable protecting group, such as Bn). Ring closure to Id can be followed by a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester to afford le. Oxidation of the methyl sulfide to the corresponding sulfinyl can be followed by addition of alcohol 1g to provide heteroaryl ether Ih. Removal of the O-protecting group to reveal alcohol li can be followed by reaction with a suitable sulfonyl chloride to provide Ij, then Boc -deprotection can reveal Ik. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 11.
[0858] Scheme 2
[0859]
[0860]
[0172] Alternatively, in some embodiments, a compound of Formula 11 may be prepared according to Scheme 2.Attorney Docket No. 56690-815601
[0861] For example, a cross-coupling reaction (e.g., a Suzuki reaction) between heteroaryl chloride Id and a suitable boronic acid or boronic ester can afford 2a. Oxidation of the methyl sulfide to the corresponding sulfinyl (2b) can be followed by addition of alcohol 1g to provide heteroaryl ether 2c. Removal of the O-protecting group (e.g., wherein PG is Bn) to reveal alcohol 2d can be followed by reaction with a suitable sulfonyl chloride to provide 2e.
[0862] Deprotection and substitution with DG can provide the compound of Formula 11, as described in Scheme 1.
[0863] Scheme 3
[0864]
[0865]
[0173] In some embodiments, a compound of Formula 11 may be prepared according to Scheme 3. For example, oxidation of Id can provide sulfinyl 3a. Addition of alcohol 1g to provide heteroaryl ether 3b can be followed by a cross coupling reaction (e.g., a Suzuki reaction) with a suitable boronic acid or ester to provide the compound of Formula 2c, which can be converted to the compound of Formula 11 as described in Scheme 2.
[0866] Scheme 4
[0867]
[0868]
[0174] In some embodiments, a compound of Formula 11 may be prepared according to Scheme 4. For example, heteroaryl ether 4b can be formed from chloride la via a nucleophilic aromatic substitution reaction with alcohol 4a.
[0869] Ring closure to 4c can be followed by a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester to afford 4d. Oxidation of the methyl sulfide to the corresponding sulfinyl (4e) can be followed by addition of alcohol 1g to provide heteroaryl ether 4f. The Cbz-protecting group can be removed to reveal amine 4g, which can be converted to Ik via a peptide coupling reaction with a suitable carboxylic acid. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 11.
[0870] Scheme 5
[0871]
[0872]
[0175] In some embodiments, a compound of Formula 11 may be prepared according to Scheme 5. For example, oxidation of the methyl sulfide to the corresponding sulfinyl (5a) can be followed by addition of alcohol 1g toAttorney Docket No. 56690-815601
[0873] provide heteroaryl ether 5b. Next, a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid orboronic ester can afford 4f, which can be converted in 3 steps described in Schemes 1 and 4 to the compound of Formula 11.
[0874] Scheme 6
[0875]
[0876]
[0176] In some embodiments, a compound of Formula 6j may be prepared according to Scheme 6. For example, heteroaryl amine 6b can be formed by reacting alcohol la with amine 6a. Conversion of the terminal alkene to boronic acid 6c can be followed by a Suzuki reaction and oxidation to form the cyclized product (6d). Addition of alcohol 1g to provide heteroaryl ether 6e can be followed by a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester to afford 6f. Removal of the Cbz-protecting group (6g) and peptide coupling with a suitable carboxylic acid can provide 6h. Finally, Boc-deprotection (6i) and an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 6j.
[0877] Scheme 7
[0878]
[0879]
[0177] In some embodiments, a compound of Formula 7j may be prepared according to Scheme 7. For example, heteroaryl ether 7b can be formed from chloride la via a nucleophilic aromatic substitution reaction with alcohol 7a.
[0880] Ring closure to 7c can be followed by a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroarylAttorney Docket No. 56690-815601
[0881] chloride and a suitable boronic acid or boronic ester to afford 7d. Oxidation of the methyl sulfide to the corresponding sulfinyl (7e) can be followed by addition of alcohol 1g to provide heteroaryl ether 7f. Global deprotection to provide 7g can be followed by peptide coupling with a suitable carboxylic acid to provide 7i, then an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 7j.
[0882] Scheme 8
[0883]
[0884]
[0178] In some embodiments, a compound of Formula 8f may be prepared according to Scheme 8. For example, addition of a suitable RB2to sulfinyl 7e can provide 8a. Next, a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester (8b) can install the RB7group of 8c, wherein PG is a suitable protecting group (e.g., Boc). Global deprotection to provide 8d can be followed by peptide coupling with a suitable carboxylic acid to provide 8e. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 8f.
[0885] Scheme 9
[0886]
[0887]
[0179] In some embodiments, a compound of Formula 9j may be prepared according to Scheme 9. For example,Attorney Docket No. 56690-815601
[0888] heteroaryl ether 9b can be formed from chloride la via a nucleophilic aromatic substitution reaction with alcohol 9a.
[0889] Ring closure to 9c can be followed by oxidation to sulfone 9d. Addition of a suitable RB2group can provide 9e, then a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester can afford 9f. Removal of the O-TBS group to reveal alcohol 9g can be followed by reaction with a suitable sulfonyl chloride to provide 9h, then Boc-deprotection can reveal 9i. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 9j.
[0890] Scheme 10
[0891]
[0892]
[0180] In some embodiments, a compound of Formula lOh may be prepared according to Scheme 10. For example, oxidation of methyl sulfide 4c to sulfone 10a can be followed by addition of a suitable alcohol to install the RB2group of 10b. Next, a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester (10c) can afford lOd, which can be followed by Cbz protection to afford lOe.
[0893] Peptide coupling with a suitable carboxylic acid can provide lOf, then Boc-deprotection can reveal 10g. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula lOh.
[0894] Scheme 11
[0895]
[0896]
[0181] In some embodiments, a compound of Formula lie may be prepared according to Scheme 11. For example, a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride and a suitable boronic acid or boronic ester can afford Ila. Removal of the O-TBS group to reveal alcohol 11b can be followed by reactionAttorney Docket No. 56690-815601
[0897] with a suitable sulfonyl chloride to provide 11c, then Boc-deprotection can reveal lid. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula lie.
[0898] Scheme 12
[0899]
[0900]
[0182] In some embodiments, a compound of Formula 12e may be prepared according to Scheme 12. For example, a cross-coupling reaction (e.g., a Suzuki reaction) between the heteroaryl chloride of 9e and a suitable boronic acid or boronic ester can afford 12a. Removal of the O-TBS group to reveal alcohol 12b can be followed by reaction with a suitable sulfonyl chloride to provide 12c, then Boc-deprotection can reveal 12d. Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 12e.
[0901]
[0183] In embodiments of the Schemes 1-12, X1is selected from N and C(Rg); and Ra, Rb, Re, Rd, Re, and Rf are independently selected from the values of the variables at the corresponding positions of the formulae in any aspect or embodiment described herein. All variables in General Schemes 1-12 that are recited in any aspect or embodiment herein are selected from the values of each corresponding variable in the formulae of the aspect or embodiment.
[0902] Scheme 13
[0903]
[0904]
[0184] In some embodiments, a compound of Formula 13k may be prepared according to Scheme 13. For example, heteroaryl ether 13c can be formed from chloride 13a via a nucleophilic aromatic substitution reactionAttorney Docket No. 56690-815601
[0905] with alcohol 13b (e.g., wherein PG is a suitable protecting group, such as Bn). Ring closure to 13d can be followed by substitution of the methyl sulfide in one or more steps with a suitable alcohol (13e) to afford 13f. For example, oxidation of methyl sulfide 13d to the corresponding sulfone can be followed by addition of alcohol 13e.
[0906] Alternatively, the methyl sulfide can be converted to the corresponding chloride using sulfonyl chloride, then reacted with alcohol 13e to provide aryl ether 13f. Substitution of the heteroaryl chloride with a suitable boronic acid or boronic ester (13g) can provide the corresponding RB7-substituted compound (13h). Removal of the O-protecting group to reveal alcohol 13i can be followed by reaction with a suitable sulfonyl chloride to provide 13j.
[0907] Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 13k.
[0908] Scheme 14
[0909]
[0910]
[0185] Alternatively, a compound of Formula 13k may be prepared according to Scheme 14. For example, heteroaryl ether 14b can be formed from chloride 13a via a nucleophilic aromatic substitution reaction with alcohol 14a. Ring closure to 14c can be followed by oxidation of the methyl sulfide to sulfone 14d using a suitable oxidant, such as mCPB A. Addition of alcohol 13e can provide aryl ether 14e. Deprotection of the adamantyl carbamate to reveal amine 14f can be followed by installation of the sulfonyl ester to afford 14g, optionally using (R)-2-((ethylsulfonyl)oxy)butanoate. Substitution of the heteroaryl chloride with a suitable boronic acid or boronic ester (13g) can provide the corresponding RB7-substituted compound (13j). Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 13k.
[0911] Scheme 15Attorney Docket No. 56690-815601
[0912]
[0913]
[0186] In still other embodiments, a compound of Formula 13k may be prepared according to Scheme 15. For example, heteroaryl ether 15b can be formed from chloride 13a via a nucleophilic aromatic substitution reaction with alcohol 15a. Ring closure to 15c can be followed by oxidation of the methyl sulfide to sulfone 15d using a suitable oxidant, such as mCPB A. Addition of alcohol 13e can provide aryl ether 14g, then substitution of the heteroaryl chloride with a suitable boronic acid or boronic ester (13g) can provide the corresponding RB7-substituted compound (13j). Finally, an SN2 reaction with a degradation enhancer (DG) can provide the compound of Formula 13k.
[0914]
[0187] In certain aspects, the present disclosure provides a compound selected from Table 1, or a pharmaceutically acceptable salt or solvate thereof. In certain aspects, the present disclosure provides a pharmaceutical composition comprising (i) a compound described herein (including compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), ora pharmaceutically acceptable salt or solvate thereof, and (ii) a pharmaceutically acceptable excipient. In embodiments, a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8)), encompasses a compound of Table 1. In embodiments, a compound of Table 1 is a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (aO), (aO-1), (aO-2), (aO-3), (A), (A-1), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8). In embodiments, a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (A), (A-l), (A-2), or (A-3), encompasses a compound of Table 1. In embodiments, a compound of Table 1 is a compound of Formula (AO), (AO-1), (AO-2), (AO-3), (A), (A-l), (A-2), or (A-3). In embodiments, a compound of Formula (aO), (aO-1), (aO-2), (aO-3), (a), (a-l), (a-2), or (a-3), encompasses a compound of Table 1. In embodiments, a compound of Table 1 is a compound of Formula (aO), (aO-1), (aO-2), (aO-3), (a), (a-l), (a-2), or (a-3).
[0915]
[0188] It will be understood that when a compound is described as “inhibiting” a target (e.g., Ras, K-Ras, mutant Ras, mutant K-Ras such as K-Ras G12D) or a compound is described as an “inhibitor” of a target, the compound may reduce the inherent activity of the target (e.g., as measured by a biochemical, cell-based, or in vivo measurement assay) or the compound may reduce the level of expression of the target in an assay, cell, animal (e.g., rodent, monkey, dog), or human subject. For example, a compound may inhibit a target by reducing the level of the target protein in a cell or subject and thereby reducing the activity of the target in cell relative to the absence of the compound. In embodiments, a compound may inhibit a target by increasing the rate of degradation of the targetAttorney Docket No. 56690-815601
[0916] protein compared to the rate of degradation of the target protein in the absence of the compound. In embodiments, a compound may inhibit a target by increasing the degradation of the target protein compared to the absence of the compound and thereby reducing the amount of the target protein present in a cell, subject, or assay.
[0917]
[0189] In some embodiments, a compound disclosed herein inhibits wildtype K-Ras or K-Ras G12D with an IC50of less than 500 nM, such as less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 90 nM, less than 80 nM, less than 70 nM, less than 60 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, or less than 10 nM, as assessed by an in vitro assay described herein. In some embodiments, a compound described herein inhibits proliferation of a cell line that expresses K-Ras or K-Ras G12D with an IC50of less than 5000 nM, such as less than 4000 nM, less than 3000 nM, less than 2000 nM, less than 1000 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, or less than 100 nM, as assessed by an in vitro cell proliferation assay.
[0918]
[0190] In some embodiments, a compound disclosed herein, exhibits selective and potent inhibition of K-Ras G12D relative to wildtype K-Ras or other K-Ras mutants (e.g., K-Ras G12V, K-Ras G12S, or K-Ras G12C).
[0919]
[0191] In some embodiments, a compound described herein, such as a compound of Formula (A0), (A0-1), (AO-21, (A0-3), (aO), (a0-l), (aO-2), (a0-3), (A), (A-l), (A-2), (A-3), (A-7), (A-8), (a), (a-l), (a-2), (a-3), (a-7), or (a-8), is provided as a substantially pure stereoisomer. In some embodiments, the stereoisomer is provid...
Claims
Attorney Docket No. 56690-815601CLAIMS WHAT IS CLAIMED IS:
1. A compound of Formula (A):or a pharmaceutically acceptable salt or solvate thereof, wherein:Z1is selected from N and N(RBlb);Z2is selected from C(RB2) and C(O);Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);Z7is selected from C(RB7) and N(RB7b);Z8is selected from C(RB8), C(RB8)2, and N;Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB2°;J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°;DG is a degradation enhancer;nl is selected from 1, 2, and 3;RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) areAttorney Docket No. 56690-815601optionally substituted with one, two, or three RB2°;RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;RB9is independently selected at each occurrence from hydrogen and RB2°;RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each ofAttorney Docket No. 56690-815601which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; andindicates a single or double bond such that all valences are satisfied.
2. The compound, salt, or solvate of claim 1, wherein the degradation enhancer is capable of binding a protein selected from E3 A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperon-mediated autophage), SCFb-TRCP (Skip-Cullin-F box (Beta-TRCP) ubiquitin complex), b-TRCP (b-transducing repeatcontaining protein), cIAPl (cellular inhibitor of apoptosis protein 1), APC / C (anaphase-promoting complex / cyclosome), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, iberdomide, and CC-885.
3. The compound, salt, or solvate of claim 1, wherein the degradation enhancer is capable of binding a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1.
4. The compound, salt, or solvate of any one of the preceding claims, wherein DG is selected from:wherein:J4is selected from a bond, 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3-to 10-membered heteroalkynylene, wherein 2- to 10-membered heteroalkylene, 3- to 10-membered heteroalkenylene, and 3- to 10-membered heteroalkynylene are optionally substituted with one or more RB20;RB15is selected from hydrogen, C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle, wherein C1-6 alkyl, C3-8 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more RB20;RB16is selected from hydrogen, C1-6 alkyl, -ORB12, -C(O)ORB12, and -C(O)RB12, wherein C1-6 alkyl is optionally substituted with one or more RB20;RB17is selected from halogen, -CN, C1-3 alkyl, C3-6 carbocycle, 4- to 6-membered heterocycle, and -S(O)2CH3, wherein C1-3 alkyl, C3-6 carbocycle, and 4- to 6-membered heterocycle are optionally substituted with oneAttorney Docket No. 56690-815601or more RB20;ol is selected from 0, 1, and 2;pl and ql are independently selected from 1, 2, and 3;X is selected from CH2and C(O);RB20is independently selected at each occurrence from halogen, oxo, -CN, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, - S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, - S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);RB21is independently selected at each occurrence from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3- 12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle); andRB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle.
5. The compound, salt, or solvate of any one of the preceding claims, wherein DG is6. A method of preparing a compound of Formula (A):Attorney Docket No. 56690-815601the method comprising:(a) reacting a compound of Formula (a):with a degradation enhancer under conditions to effect release of LG and production of the compound of Formula (A), wherein:Z1is selected from N and N(RBlb);Z2is selected from C(RB2) and C(O);Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);Z7is selected from C(RB7) and N(RB7b);Z8is selected from C(RB8), C(RB8)2, and N;Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;J1is selected from a bond, Ci-e alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;J2is selected from a bond, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB2°;J3is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB2°;DG is a degradation enhancer;LG is a leaving group;nl is selected from 1, 2, and 3;RBlb, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,Attorney Docket No. 56690-8156012- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i2carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;RB9is independently selected at each occurrence from hydrogen and RB2°;RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB20;RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-12 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB2° attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -C0-6 alkyl-(C3-12 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-12 carbocycle), -C0-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23),Attorney Docket No. 56690-815601=NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);RB21is independently selected at each occurrence from hydrogen, halogen, CN, Ci-6 alkyl, Ci-6 haloalky 1, -Co-6 alkyl-(C3-i2carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; andindicates a single or double bond such that all valences are satisfied.
7. A compound of Formula (a):or a pharmaceutically acceptable salt or solvate thereof, wherein:Z1is selected from N and N(RBlb);Z2is selected from C(RB2) and C(O);Z6is selected from C(RB6), C(RB6)2, N, and N(RB6b);Z7is selected from C(RB7) and N(RB7b);Z8is selected from C(RB8), C(RB8)2, and N;Q2is 4- to 12-membered heterocycle optionally substituted with one or more RB2°;J1is selected from a bond, Ci-e alkylene, C2-e alkenylene, C2-e alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -O-, -N(RB12)-, -C(O)-, -N(RB12)C(O)-, -C(O)N(RB12)-, -S-, -S(O)2-, -S(O)-, -P(O)RB12-, -N(RB12)S(O)2-, -N(RB12)S(O)-, -N(RB12)P(O)RB12-, -S(O)2N(RB12)-, -S(O)N(RB12)-, -P(O)RB12N(RB12)-, -OS(O)2-, -OS(O)-, -OP(O)RB12-, -S(O)2O-, -S(O)O-, and -P(O)RB12O-, wherein C1-6 alkylene, C2-e alkenylene, C2-e alkynylene, 2- to 6-membered heteroalkylene, 3- to 6-membered heteroalkenylene, and 3- to 6-membered heteroalkynylene are optionally substituted with one or more RB2°;J2is selected from a bond, -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, wherein -Co-6 alkyl-(C3-i2carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)- are optionally substituted with one or more RB2°;J3is selected from Ci-e alkylene, C2-e alkenylene, C2-e alkynylene, 2- to 6-membered heteroalkylene, 3- toAttorney Docket No. 56690-8156016-membered heteroalkenylene, 3- to 6-membered heteroalkynylene, -Co-6 alkyl-(C3-i2 carbocycle)-, -(2- to 6-membered heteroalkyl)-(C3-12carbocycle)-, -Co-6 alkyl-(3- to 12-membered heterocycle)-, and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle)-, each of which is optionally substituted with one or more RB20;LG is selected from -OS(O)2RB4and -OS(O)(NRB4b)RB4;nl is selected from 1, 2, and 3;RB4is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), and -N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;RBlb, RB4b, RB6b, and RB7bare independently selected from hydrogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -C(O)ORB12, -C(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one, two, or three RB2°;RB2, RB6, RB7, and RB8are independently selected at each occurrence from hydrogen, halogen, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB12, -SRB12, -N(RB12)(RB13), -C(O)ORB12, -OC(O)N(RB12)(RB13), -N(RB12)C(O)N(RB12)(RB13), -N(RB12)C(O)ORB12, -N(RB12)S(O)2RB12, -C(O)RB12, -S(O)RB12, -OC(O)RB12, -C(O)N(RB12)(RB13), -C(O)C(O)N(RB12)(RB13), -N(RB12)C(O)RB12, -S(O)2RB12, -S(O)(NRB12)RB12, -S(O)2N(RB12)(RB13), and -S(=O)(=NRB12)N(RB12)(RB13), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalky l)-(C3-i 2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), and -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;RB9is independently selected at each occurrence from hydrogen and RB2°;RB12is independently selected at each occurrence from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle) are optionally substituted with one or more RB2°;RB13is independently selected at each occurrence from hydrogen, C1-6 alkyl, and C1-6 haloalkyl; or RB12and RB13attached to the same nitrogen atom form 3- to 10-membered heterocycle optionally substituted with one or more RB2°;RB2° is independently selected at each occurrence from halogen, oxo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6Attorney Docket No. 56690-815601alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23)-, and -S(=O)(=NRB22)N(RB22)(RB23); wherein two RB20attached to the same or adjacent atoms optionally join to form C3-12 carbocycle or 3- to 12-membered heterocycle; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 2- to 6-membered heteroalkyl, 3- to 6-membered heteroalkenyl, 3- to 6-membered heteroalkynyl, -Co-6 alkyl-(C3-i2 carbocycle), -(2- to 6-membered heteroalkyl)-(C3-i2 carbocycle), -Co-6 alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalky l)-(3 - to 12-membered heterocycle), C3-12 carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, -ORB22, -SRB22, -N(RB22)(RB23), =NRB22, =C(RB21)2, -SF5, =N-ORB22, =N-N(RB22)(RB23), -P(O)(RB22)(RB23), -ON=RB22, -C(O)ORB22, -OC(O)N(RB22)(RB23), -N(RB22)C(O)N(RB22)(RB23), -N(RB22)C(O)ORB22, -N(RB22)S(O)2RB22, -C(O)RB22, -S(O)RB22, -OC(O)RB22, -C(O)N(RB22)(RB23), -C(O)C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, -S(O)2RB22, -S(O)(NRB22)RB22, -S(O)2N(RB22)(RB23), and -S(=O)(=NRB22)N(RB22)(RB23);RB21is independently selected at each occurrence from hydrogen, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-i2 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle), or two RB21are taken together with the carbon atom to which they are attached to form C3-12 carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl, C1-3 haloalkyl, and -OH;RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -Co-6 alkyl-(C3-12 carbocycle), and -Co-6 alkyl-(3- to 12-membered heterocycle);RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl; or RB22and RB23attached to the same nitrogen atom form 3- to 10 membered heterocycle; andindicates a single or double bond such that all valences are satisfied.
8. The compound, salt, solvate, or method of any one of the preceding claims, wherein nl is 1.
9. The compound, salt, solvate, or method of any one of the preceding claims, wherein Q2is 7- to 9-membered bridged bicyclic heterocycloalkyl optionally substituted with one or more RB20.
10. The compound, salt, solvate, or method of claim 9, wherein, which is optionally substituted with one or more RB2°.
11. The compound, salt, solvate, or method of any one of the preceding claims, wherein:Z1is N, Z2is C(RB2), Z6is C(RB6), Z7is C(RB7), and Z8is C(RB8);Z1is N, Z2is C(RB2), Z6is N, Z7is C(RB7), and Z8is C(RB8);Z1is N, Z2is C(RB2), Z6is C(RB6)2, Z7is N(RB7b), and Z8is C(RB8)2; orZ1is N(RBlb), Z2is C(O), Z6is C(RB6), Z7is C(RB7), and Z8is N.Attorney Docket No. 56690-81560112. The compound, salt, solvate, or method of claim 11, wherein Z1is N, Z2is C(RB2), Z6is C(RB6), Z7is C(RB7), and Z8is C(RB8).
13. The compound, salt, solvate, or method of claim 11, wherein Z1is N, Z2is C(RB2), Z6is N, Z7is C(RB7), and Z8is C(RB8).
14. The compound, salt, solvate, or method of any one of the preceding claims, wherein J1is selected from a bond, Ci-6 alkylene, 2- to 6-membered heteroalkylene, and -C(O)-, wherein Ci-6 alkylene and 2- to 6-membered heteroalkylene are optionally substituted with one or more RB20.
15. The compound, salt, solvate, or method of any one of the preceding claims, wherein J1is -C(O)-.
16. The compound, salt, solvate, or method of any one of the preceding claims, wherein J2is a bond.
17. The compound, salt, solvate, or method of any one of the preceding claims, wherein J3is selected from Ci-6 alkylene and 2- to 6-membered heteroalkylene, each of which is optionally substituted with one or more RB20.
18. The compound, salt, solvate, or method of any one of the preceding claims, wherein:J1is -C(O)-;J2is a bond; andJ3is C1-6 alkylene.
19. The compound, salt, solvate, or method of claim 1 or 6, having the formula:
20. The compound, salt, solvate, or method of claim 6 or 7, having the formula:
21. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is selected from:(i) -O(Ci.3 alkylene) -(C3-5 carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23),Attorney Docket No. 56690-815601=C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein Ci-6alkyl, C3-4carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, Ci-6 alkyl, and Ci-6 haloalkyl; RB22is independently selected at each occurrence from hydrogen, Ci-6 alkyl, Ci-6 haloalkyl, C3-4 carbocycle, and 3- to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and Ci-e alkyl;(ii) -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein the (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle;(iii) -O(C2.3 alkylene)(pyrrolidine), wherein the pyrrolidine is substituted with two or three substituents independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2;(iv) -O(Ci-3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms) optionally substituted with one unsubstituted C1-3 alkyl; and(v) -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence from hydrogen and halogen.
22. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is -O(C1-3 alkylene)-(C3-5 carbocycle)-(C1-3 alkylene)-(6- to 8-membered heterocycle), wherein the 6- to 8-membered heterocycle comprises two ring nitrogen atoms, and wherein -O(Ci-3 alkylene)-(C3-s carbocycle)-(Ci-3 alkylene)-(6- to 8-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, oxo, -CN, C1-6 alkyl, C3-4 carbocycle, 3- to 8-membered heterocycle, -ORB22, -N(RB22)(RB23), =C(RB21)2, -C(O)RB22, -C(O)N(RB22)(RB23), -N(RB22)C(O)RB22, and -S(O)2RB22; wherein C1-6 alkyl, C3-4 carbocycle, and 3- to 8-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -N(RB22)(RB23), and -N(RB22)C(O)RB22; RB21is independently selected at each occurrence from hydrogen, halogen, CN, Ci -6 alkyl, and C1-6 haloalkyl; RB22is independently selected at each occurrence from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-4 carbocycle, and 3- to 4-membered heterocycle; and RB23is independently selected at each occurrence from hydrogen and C1-6 alkyl.
23. The compound, salt, solvate, or method of any one of claims 1 to 20, whereinAttorney Docket No. 56690-81560124. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl, C0-1 alkyl-(C3-e carbocycle), and 4- to 6-membered heterocycle.
25. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is selected fromAttorney Docket No. 56690-81560126. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is -O(Ci-3 alkylene)(5-membered partially unsaturated heterocycle comprising one ring nitrogen atom), wherein (5-membered partially unsaturated heterocycle comprising one ring nitrogen atom) is substituted with two or three substituents independently selected from C1-3 alkyl.
27. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is selected from28. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is -O(C2-3 alkylene)(pyrrolidine), wherein the pyrrolidine is substituted with two or three substituents independently selected from Ci.3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2.
29. The compound, salt, solvate, or method of claim 28, whereinR20is independently selected from C1-3 alkyl optionally substituted with one or more substituents independently selected from halogen, C3-4 carbocycle, -NH2, and -N(CH3)2.The compound, salt, solvate, or method of any one of claims 1 to 20, wherein31. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is -O(Ci-3 alkylene)(7- to 8-membered bridged heterocycle comprising one or two ring nitrogen atoms) optionally substituted with one unsubstituted C1-3 alkyl.
32. The compound, salt, solvate, or method of any one of claims 1 to 20, whereinAttorney Docket No. 56690-81560133. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered bridged heterocycle), wherein the 8- to 10-membered bridged heterocycle comprises one or two ring heteroatoms, and wherein -O(Ci-3 alkylene)-(C3-5 carbocycle)-(Ci-3 alkylene)-(8- to 10-membered heterocycle) is optionally substituted with one, two, or three substituents independently selected from halogen, C1-3 alkyl, 4- to 7-membered heterocycle, and =C(RB21)2; wherein C1-3 alkyl is optionally substituted with one or more halogen; and RB21is independently selected at each occurrence from hydrogen and halogen.
34. The compound, salt, solvate, or method of any one of claims 1 to 20, wherein RB2is selected from35. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB6is halogen or C1-3 haloalkyl.
36. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB7is selected from Ce-i2 aryl and 5- to 12-membered heteroaryl, each of which is optionally substituted with one or more RB20.
37. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB7is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more RB2°38. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, C2-3 alkynyl, -ORB22, -N(RB22)(RB23), and C3-6 cycloalkyl.
39. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB7is substituted with one, two, three, or four substituents independently selected from halogen, -CN, -CH3, -CH2CH3, -CH=CH2, -CF3, -C≡CH, -OH, -NH2, and -cyclopropyl.
40. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB7is selected fromAttorney Docket No. 56690-81560141. The compound, salt, solvate, or method of any one of claims 1 to 40, wherein RB7is selected from42. The compound, salt, solvate, or method of any one of the preceding claims, wherein RB8is halogen.
43. The compound, salt, solvate, or method of any one of claims 1 to 34, wherein:RB6is halogen;RB7is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more RB20; andRB8is halogen.
44. A compound selected from Table 1, or a pharmaceutically acceptable salt or solvate thereof.
45. A pharmaceutical composition comprising a compound of any one of claims 1 to 5 or 7 to 44, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.Attorney Docket No. 56690-81560146. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 5 or 7 to 44, or a pharmaceutically acceptable salt or solvate thereof.
47. A method of treating cancer in a subject comprising a Ras mutant protein, the method comprising: inhibiting the Ras mutant protein of said subject by administering to said subject a compound of any one of claims 1 to 5 or 7 to 44, wherein the compound is characterized in that upon contacting the Ras mutant protein, said Ras mutant protein exhibits reduced Ras signaling output.
48. A method of reducing signaling output of a Ras protein, comprising contacting a Ras protein with an effective amount of a compound of any one of claims 1 to 5 or 7 to 44, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing the signaling output of the Ras protein.
49. The method of claim 48, wherein the compound binds covalently or non-covalently to the Ras protein, thereby reducing the signaling output of the Ras protein.
50. A method of inhibiting cell growth, comprising administering an effective amount of a compound of any one of claims 1 to 5 or 7 to 44, or a pharmaceutically acceptable salt or solvate thereof, to a cell expressing a Ras protein, thereby inhibiting growth of said cells.
51. The method of any one of claims 46 to 50, comprising administering an additional agent.
